


図⑧ $[^{125}\text{I}]\text{IB12-Ex}$ (9-39) の SPECT 画像 (マウス)

(9-39) の脾臓集積は GLP-1R への結合によるものであることを認めた。以上、脾臓β細胞イメージングの PET 用プローブとして $[^{18}\text{F}]\text{FB40-Ex}$ (9-39)、SPECT 用プローブとして $[^{125}\text{I}]\text{IB12-Ex}$ (9-39) を開発することに成功し、現在、臨床研究を実施するために、安全性・毒性試験を行っている。

(4) 悪性腫瘍の HIF-1 α 存在領域イメージングプローブの創製

悪性腫瘍を対象とした分子イメージングプローブであるグルコース誘導体 ^{18}F -FDG が、腫瘍の病期診断、再発・転移診断など、主として腫瘍の存在の有無やサイズを評価するために用いられている。一方で、浸潤・転移能や治療反応性など、腫瘍の性質は非常に多様性に富むことが知られており、腫瘍の性状把握、さらには質的診断ができる臨床画像診断のための分子イメージングプローブの開発がポスト FDG として期待されている。

HIF-1 α は低酸素領域でのみ安定に存在する転写因子であり、糖代謝・血管新生・浸潤・転移に関与する種々のタンパク質発現を亢進させて腫瘍の悪性化や治療抵抗性に関与することが知られていることから、腫瘍内での HIF-1 α 存在量やその局在を同定できる分子プローブが開発できれば、腫瘍の性状把握、悪性度診断、予後予測などに有用な情報を得ることが可能となる。もっとも、HIF-1 α は生体組織が酸素不足を感じる生物学的


低酸素領域に存在しており、その領域は酸素分圧が 10 mmHg 以下のいわゆる物理的低酸素領域と完全には一致せずに組織によって異なることから、HIF-1 α 存在領域イメージングプローブはこれまでに開発されている物理的低酸素領域イメージングプローブとは異なる情報を与えることが期待される。そこでわれわれは、この HIF-1 α 存在領域イメージングプローブの開発を計画した。

HIF-1 は α サブユニット (HIF-1 α) と β サブユニットからなり、HIF-1 α は通常酸素環境下では分解される一方、低酸素環境下では安定に存在することで転写活性を調節している。そこでわれわれは、HIF-1 α 存在領域のイメージングプローブの開発にあたり、この HIF-1 α の分解機構に着目して HIF-1 α と同じメカニズムで分解・安定化の制御を受けるプローブを開発することとした。その分子設計の概念を図⑨ A に示す。すなわち、HIF-1 α 分子の中で通常酸素環境下での分解に関与する酸素依存的分解配列 (oxygen-dependent degradation domain: ODD) (標的認識ユニット) に、高分子ペプチドの細胞膜透過を促進する低分子ペプチド (protein transduction domain: PTD) および、放射性ビオチン誘導体が特異的に結合できるストレプトアビジン (SAV) 単量体 (リンカーユニット) を結合させた新規タンパク質 PTD-ODD-SAV (POS) を構築する。この POS を生体に投与すると、POS は通常酸素状態にある組織・臓器では分解し、低酸素環境下では安定に存在することとなる。そこで、この低酸素環境下組織でのみ POS が存在している状態で、POS の SAV と特異的に結合する放射線標識ビオチン誘導体 [PET 用として (4- $[^{18}\text{F}]\text{fluorobenzoyl}$) norbiotinamide; ^{18}F -FBB, SPECT 用として (4- $[^{125}\text{I}]\text{iodobenzoyl}$) norbiotinamide; ^{125}I -IBB] (ビオチン部分は「リンカーユニット」、 ^{18}F および ^{125}I 部分は「シグナルユニット」) を投与すると、特異性高く結合するストレプトアビジンとビオチンとの結合により、 ^{18}F -FBB または ^{125}I -IBB は POS に特異的に結合して POS が存在している領域のみに存在することとなり、HIF-1 α 存在領域を特異的にイメージングすることができることとなる (インビボカップリング法)。

第5章

ナノバイオ技術を応用した薬物・細胞動態の制御と評価

図9 悪性腫瘍における HIF-1 α 存在領域の分子イメージングプローブ (*in vivo* 結合型) の分子設計概念とそれによる腫瘍移植動物でのイメージング



そこで POS, ^{18}F -FBB, ^{123}I -IBB をそれぞれ開発し、まず POS を担癌マウスに投与し、次いで 24 時間後に ^{18}F -FBB または ^{123}I -IBB を投与したところ、その投与 3 時間後において腫瘍に集積した放射能は POS 非投与群 (^{18}F -FBB または ^{123}I -IBB のみ投与群) の 20 倍以上となり、明瞭な腫瘍のイメージングに成功した³⁰⁾⁻³²⁾ (図9 B)。また、その集積は過剰量のビオチン投与によって抑制されたことから、 ^{18}F -FBB または ^{123}I -IBB が所期のとおりに、POS の SAV 部分とインビボでカップリングすることが示された。さらに、その時のマウスの切片を作製してオートラジオグラフィを行ったところ、放射能集積量および局在が HIF-1 転写活性や存在領域と一致することを認めた³⁾。さらに、今回開発したインビボカップリング法は、短半減期核種を利用する核医学分子イメージングにおいて、HIF-1 α 存在低酸素領域イメージングだけでなく、非特異的集積部位からの消失が遅い抗体や高分子化合物、ペプチドなどの場合にも有効なイメージング法であることを明らかにした。

おわりに

生体分子イメージングは、医薬品開発、臨床画像診断に極めて有効な手法になると期待され、実際有効例も多く報告されつつあり、さらには実用展開も図れている。この手法は、生理状態および疾患時での分子の活動情報を可視化して、疾患の分子機構と医薬品の標的を含めて治療の標的とを結びつけ、医薬品開発や治療に還元することを可能とする。放射性分子プローブを用いる核医学イメージングは現在臨床での分子イメージングの中心となっているが、今後は、核医学、MRI、X線、光などの手法を組み合わせるマルチモダリティによって総合的な分子の情報を得ることが、分子イメージングを医薬品開発、診断・治療評価などの分野にさらに広く展開させていくためには重要となるであろう。実際、われわれも光イメージングや MRI のための分子プローブの開発も行い、その有効性を示している²⁵⁾³³⁾⁻³⁵⁾。さらに、われわれが提案する「機能性ユニット結合型分子プ

ローブ」という分子プローブ設計の概念は、適切な標的分子を把握しうる「標的認識ユニット」および各モダリティに対応した「シグナルユニット」を組み合わせることで、種々の分子プローブを効

率よく開発できる分子設計法であることから、今後マルチモダリティによる総合的な分子イメージングを展開していくために必要な分子プローブの開発に有効なものとなると期待される。

参考文献

- 1) Weissleder R, Mahmood U : Radiology 219, 316-333, 2001.
- 2) Thakur M, Lentle BC : Radiology 236, 753-755, 2005.
- 3) Rudin M, Weissleder R : Nat Rev Drug Discov 2, 123-131, 2003.
- 4) Hargreaves RJ : Clin Pharmacol Ther 83, 349-353, 2008.
- 5) Weber WA, Czernin J, et al : Nat Clin Practice Oncol 5, 44-54, 2008.
- 6) Lappin G, Garner RC : Nat Rev 2, 233-240, 2003.
- 7) Saleem A, Harte RJ, et al : J Clin Oncol 19, 1421-1429, 2001.
- 8) 佐治英郎 : 創薬研究への分子イメージング応用 (佐治英郎編), メディカルドゥ, 37-46, 2010.
- 9) Ogawa M, Ishino S, et al : J Nucl Med 45, 1245-1250, 2004.
- 10) Ogawa K, Mukai T, et al : J Nucl Med 47, 2042-2047, 2006.
- 11) Ishino S, Mukai T, et al : J Nucl Med 49, 1677-1685, 2008.
- 12) Ono M, Ikeoka R, et al : ACS Chemical Neuroscience 1, 598-607, 2010.
- 13) Ono M, Ikeoka R, et al : ACS Med Chem Lett 1, 443-447, 2010.
- 14) Temma T, Ogawa Y, et al : J Nucl Med 51, 1979-1986, 2010.
- 15) Kuge Y, Takai N, et al : Eur J Nucl Med Mol Imaging 37, 2093-2104, 2010.
- 16) Saji H, Ogawa M, et al : Ann Nucl Med 16, 189-200, 2002.
- 17) Ueda M, Iida Y, et al : Ann Nucl Med 18, 337-344, 2004.
- 18) Mamede M, Ishizu K, et al : J Nucl Med 45, 1458-1470, 2004.
- 19) Mamede M, Ishizu K, et al : J Nucl Med 48, 1829-1835, 2007.
- 20) Oishi N, Hashikawa K, et al : J Neurol Sci 256, 52-60, 2007.
- 21) Ono M, Yoshida N, et al : J Med Chem 48, 7253-7260, 2005.
- 22) Ono M, Kawashima H, et al : J Med Chem 49, 2725-2730, 2006.
- 23) Ono M, Hayashi S, et al : Bioorg Med Chem 17, 2069-2076, 2009.
- 24) Ono M, Watanabe R, et al : J Med Chem 52, 6394-6401, 2009.
- 25) Ono M, Hayashi S, et al : Bioorg Med Chem 17, 7002-7009, 2009.
- 26) Cheng Y, Ono M, et al : ACS Med Chem Lett 1, 321-325, 2010.
- 27) Cheng Y, Ono M, et al : Bioorg Med Chem Lett 20, 6141-6144, 2010.
- 28) Ono M, Cheng Y, et al : J Med Chem 54, 2971-2979, 2011.
- 29) Mukai E, Toyoda K, et al : Biochem Biophys Res Commun 389, 523-526, 2009.
- 30) Kudo T, Ueda M, et al : J Nucl Med 50, 942-949, 2009.
- 31) Ueda M, Kudo T, et al : Eur J Nucl Med Mol Imaging 37, 1566-1574, 2010.
- 32) Kudo T, Ueda M, et al : Mol Imaging Biol, Sep 14, 2010.
- 33) Ono M, Ishikawa M, et al : Bioorg Med Chem Lett 20, 3885-3888, 2010.
- 34) Shimizu Y, Temma T, et al : Cancer Sci 102, 1897-1903, 2011.
- 35) Sano K, Temma T, et al : Mol Imaging Biol 13, 1196-1203, 2011.

参考ホームページ

- ・ 京都大学大学院薬学研究科病態機能分析学分野
<http://www.pharm.kyoto-u.ac.jp/byotai/>
- ・ Society of Molecular Imaging
<http://www.molecularimaging.org/>
- ・ Academy of Molecular Imaging
<http://www.ami-imaging.org/>
- ・ 日本分子イメージング学会
<http://www.molecularimaging.jp/>
- ・ Society of Radiopharmaceutical Sciences
<http://www.srsweb.org/>
- ・ 放射線医学総合研究所分子イメージング研究センター
<http://www.nirs.go.jp/research/division/mic/index.html>
- ・ 理化学研究所分子イメージング研究プログラム
<http://www.cdb.riken.jp/mirp/>

佐治英郎

1974年 京都大学薬学部卒業
 1976年 京都大学大学院薬学研究科博士課程中退
 1977年 京都大学医学部助手
 1980年 米国ワシントン大学研究助手
 1988年 京都大学薬学部助教授
 1996年 同教授
 1997年 京都大学大学院薬学研究科教授 (配置換)
 2006年 京都大学放射性同位元素総合センター長 (併任)
 2008年 京都大学副理事 (併任)
 2010年 京都大学大学院薬学研究科長


Rhodanine and Thiohydantoin Derivatives for Detecting Tau Pathology in Alzheimer's Brains

Masahiro Ono,^{*,†} Shun Hayashi,[†] Kenji Matsumura,[†] Hiroyuki Kimura,[†] Yoko Okamoto,[†] Masafumi Ihara,[†] Ryosuke Takahashi,[‡] Hiroshi Mori,[§] and Hideo Saji^{*,†}[†]Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan[‡]Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan[§]Department of Neuroscience, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

Supporting Information

ABSTRACT: A novel series of rhodanine (RH) and thiohydantoin (TH) derivatives were designed and synthesized for detecting tau pathology in the brains of patients with Alzheimer's disease (AD). In experiments *in vitro* using tau and β -amyloid ($A\beta$) aggregates, the TH derivative, TH2, showed high specific binding to tau aggregates. In hippocampal sections obtained from AD patients, TH2 intensely stained neurofibrillary tangles. In experiments using normal mice, [¹²⁵I]TH2 showed good uptake (1.54%ID/g, 2 min postinjection) into and a rapid washout (0.25%ID/g, 60 min postinjection) from the brain. [¹²⁵I]TH2 should be further investigated as a potential imaging agent for detecting tau pathology.

KEYWORDS: Alzheimer's disease, tau, imaging, rhodanine, thiohydantoin



Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by abundant senile plaques (SPs) composed of β -amyloid ($A\beta$) peptides and numerous neurofibrillary tangles (NFTs) formed by filaments of highly phosphorylated tau proteins in the brain.¹ Currently, only the definitive confirmation of AD is dependent on a post-mortem histopathological examination of SPs and NFTs in the brain. Therefore, *in vivo* imaging of SPs and/or NFTs in the living brain with noninvasive techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) could lead to the presymptomatic detection of AD and new anti-amyloid therapies.^{2–4}

Extensive research has been undertaken to develop radiolabeled $A\beta$ imaging agents for targeting SPs. Clinical trials with [¹⁸F]FDDNP,^{5,6} [¹¹C]6-OH-BTA-1,^{7,8} [¹¹C]SB-13,^{9,10} [¹⁸F]BAY94–9172,^{11,12} [¹¹C]BF227,¹³ [¹²³I]IMPY,^{14–17} [¹⁸F]AV-45,^{18–20} [¹¹C]AZD2184,²¹ and [¹⁸F]AZD4694²² indicate the imaging of $A\beta$ plaques in living brain tissue to be useful for the diagnosis of AD.

While many PET/SPECT probes for SPs or $A\beta$ plaques have been developed, few compounds for targeting NFTs have been reported. Previous neuropathological research suggests that the deposition of NFTs occurs before the manifestation of clinical symptoms in AD. These reports suggest that even in the very early stages of AD, patients display considerable numbers of NFTs in the entorhinal cortex and hippocampus, sufficient for a neuropathological diagnosis. Furthermore, NFT deposition in the entorhinal cortex is closely related with neuronal loss in very early AD patients.^{23–26} Thus, *in vivo* imaging of NFTs in

conjunction with the imaging of $A\beta$ plaques is thought to be useful for the early and accurate diagnosis of AD. A quantitative evaluation of tau pathology could also be helpful for tracking the severity of dementia, because the pathology correlates well with the clinical severity of dementia.

Some papers have reported that FDDNP,²⁷ FSB,²⁸ and curcumin²⁹ can bind to not only NFTs but also $A\beta$ plaques in the brain. Quinoline and benzimidazole derivatives are also reported as candidate probes for *in vivo* imaging of tau pathology in AD.³⁰ However, these compounds are not completely specific to tau, because they also bind to $A\beta$ plaques. Currently, no PET/SPECT imaging agents targeting NFTs exist that allow an evaluation of tau pathology in AD brains.

Recently, the effects of rhodanine and thiohydantoin derivatives on the formation, extension, and destabilization of tau aggregates were studied *in vitro*.³¹ These derivatives dose-dependently inhibited the formation of tau aggregates as well as destabilized preformed tau aggregates, indicating that they could directly bind or interact with the aggregates. In the present study, we designed and synthesized three novel radioiodinated rhodanine and thiohydantoin derivatives (Figure 1) and evaluated their biological activities as *in vivo* NFT imaging agents. To our knowledge, this is the first time the use of rhodanine and thiohydantoin derivatives *in vivo* as probes to detect tau pathology in the AD brain has been proposed.

Received: January 17, 2011

Accepted: March 1, 2011

Published: March 21, 2011

RESULTS AND DISCUSSION

Chemistry. The synthesis of the rhodanine and thiohydantoin derivatives was outlined in Scheme 1. The key step in the formation of the rhodanine and thiohydantoin backbone was achieved by a Knoevenagel condensation reaction between aromatic aldehydes and the rhodanine or thiohydantoin core. The aromatic aldehydes (**1** and **8**) necessary for the Knoevenagel condensation reaction were obtained by Suzuki coupling between haloaromatics and functionalized boronic acid. The rhodanine and thiohydantoin cores (**2**, **3**, and **6**) were produced by the reaction of glycine ethyl ester or histamine with bis(carboxymethyl)trithiocarbonate or ethyl isothiocyanatoacetate in the presence of Et₃N. The





Figure 1. Chemical structure of rhodanine and thiohydantoin derivatives reported in this study.

target compounds (**4** (rhodanin **1** (RH1)), **5** (thiohydantoin **1** (TH1)) and **7** (TH2)) were obtained by the Knoevenagel condensation reaction of the aromatic aldehyde (**1**) with the rhodanine and thiohydantoin cores (**2**, **3**, and **6**) in yields of 76, 44, and 51%, respectively. The tributyltin derivative (**9**) was prepared from the corresponding bromo compound (**8**) using a bromo to tributyltin exchange reaction catalyzed by Pd(0) in a yield of 40%. The tributyltin derivatives (**10**, **11**, and **12**) were obtained by the Knoevenagel condensation reaction and used as precursors for radioiodination in the preparation of [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2. Novel radioiodinated rhodanine and thiohydantoin derivatives were obtained with an iododestannylation reaction using hydrogen peroxide as the oxidant, which produced the desired radioiodinated ligands. It was anticipated that the no-carrier-added preparation would result in a final product bearing a theoretical specific activity similar to that of ¹²⁵I (81.4 TBq/mmol). The radiochemical identities of the radioiodinated ligands were verified by coinjection with nonradioactive compounds from their HPLC profiles. The final radioiodinated compounds [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2 showed a single peak of

Scheme 1




^a Reagents: (a) (Ph₃P)₄Pd, Na₂CO₃, dimethoxyethane. (b) Bis(carboxymethyl)trithiocarbonate, Et₃N, iPrOH. (c) Ethyl isothiocyanatoacetate, Et₃N, acetonitrile. (d) piperidine, CH₂Cl₂. (e) (Bu₃Sn)₂, (Ph₃P)₄Pd, Et₃N, dioxane. (f) [¹²⁵I]NaI, H₂O₂, HCl.

Table 1. Inhibition of Thioflavin S Binding to Tau Aggregates or A β 42 Aggregates

compounds	K_i (nM) ^a	
	tau	A β 42
RH1	489 \pm 62	752 \pm 128
TH1	155 \pm 14	864 \pm 147
TH2	64 \pm 7	469 \pm 60

^a Values are the mean \pm standard error of the mean for three independent experiments.

**Figure 2.** Binding of [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2 to tau aggregates and tau monomers.

radioactivity at the retention times of 9.4 min (CH₃CN/H₂O = 4:1), 15.7 min (CH₃CN/H₂O = 3:2), and 10.5 min (CH₃CN/H₂O = 3:1), respectively. The three products were obtained in 8–22% radiochemical yields with a radiochemical purity of >95% after purification by HPLC.

To quantify the affinity of the rhodanine and thiohydantoin derivatives for tau aggregates, we carried out assays with thioflavin S as a competing ligand. These derivatives displaced thioflavin S in a dose-dependent manner, indicating that they have affinity for tau aggregates. In addition, this result suggests that these derivatives may occupy a binding site on tau aggregates similar to that of thioflavin S. The K_i values for RH1, TH1, and TH2 were 489, 155, and 64 nM, respectively (Table 1). Discrimination between tau and A β aggregates in the brain is required for the development of NFT-specific agents. To compare the affinity between tau and A β aggregates, we also carried out assays with thioflavin S as a competing ligand. RH1, TH1, and TH2 showed K_i values of 752, 864, and 469 nM, respectively, for A β aggregates. The ratio of K_i values for tau and A β aggregates was 1.54, 5.57, and 7.33 for RH1, TH1, and TH2, respectively, indicating that these derivatives displayed higher binding to tau aggregates than A β aggregates. The result also suggests the thiohydantoin derivatives to be more NFT-selective than the rhodanine derivatives.

Further investigation of the binding to tau aggregates was performed by size exclusion chromatography. A high level of radioactivity was eluted in the fraction corresponding to the tau aggregates after the incubation with [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2 (Figure 2). Conversely, little radioactivity was observed in the fraction corresponding to monomeric tau. The results suggest that these agents bind to tau aggregates not to tau monomers, as reflected by the inhibition assays.

Table 2. Biodistribution of Radioactivity after Intravenous Administration of [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2 in Mice^a

tissue	time after injection (min)			
	2	10	30	60
[¹²⁵ I]RH1				
blood	6.70 (0.53)	3.58 (0.37)	2.27 (0.44)	1.59 (0.14)
liver	43.06 (2.07)	29.52 (2.17)	14.74 (2.27)	11.30 (0.87)
kidney	8.50 (0.83)	7.64 (0.69)	6.42 (1.17)	3.91 (0.18)
intestine	1.77 (0.33)	7.97 (1.24)	15.07 (1.82)	21.03 (2.73)
spleen	6.70 (0.54)	4.11 (0.80)	2.66 (0.84)	1.94 (0.40)
pancreas	1.74 (0.19)	1.75 (0.18)	1.6 (0.17)	0.73 (0.08)
heart	9.41 (0.49)	5.05 (0.39)	2.38 (0.38)	1.39 (0.19)
stomach ^b	0.52 (0.03)	1.16 (0.16)	2.75 (0.36)	2.94 (0.51)
brain	0.23 (0.02)	0.16 (0.01)	0.15 (0.03)	0.11 (0.02)
[¹²⁵ I]TH1				
blood	9.49 (0.82)	2.38 (0.88)	1.79 (0.11)	1.50 (0.10)
liver	32.19 (1.67)	32.11 (2.09)	22.60 (3.42)	20.18 (1.93)
kidney	9.21 (0.68)	9.311 (1.15)	3.86 (0.85)	2.68 (0.75)
intestine	1.85 (0.26)	7.88 (1.46)	17.73 (2.22)	23.40 (5.37)
spleen	9.16 (2.04)	12.21 (2.28)	13.58 (4.29)	10.04 (2.49)
pancreas	1.79 (0.27)	0.98 (0.08)	0.56 (0.10)	0.45 (0.08)
heart	7.02 (1.23)	2.05 (0.29)	1.19 (0.33)	1.44 (0.39)
stomach ^b	0.62 (0.22)	2.47 (2.41)	2.13 (1.01)	3.30 (1.40)
brain	0.57 (0.07)	0.32 (0.02)	0.18 (0.02)	0.10 (0.03)
[¹²⁵ I]TH2				
blood	8.16 (1.21)	2.77 (0.21)	2.11 (0.28)	1.48 (0.27)
liver	34.99 (2.27)	33.32 (1.41)	27.22 (2.05)	22.75 (2.13)
kidney	12.48 (0.76)	7.34 (0.70)	4.97 (0.71)	3.37 (0.30)
intestine	2.55 (0.16)	7.41 (1.21)	17.32 (1.67)	23.58 (2.39)
spleen	9.23 (0.63)	10.87 (2.78)	8.51 (2.68)	8.46 (2.57)
pancreas	3.30 (0.86)	2.15 (0.23)	1.15 (0.18)	0.86 (0.08)
heart	8.48 (0.97)	2.78 (0.19)	1.73 (0.18)	1.30 (0.37)
stomach ^b	0.87 (0.07)	1.70 (1.14)	2.78 (0.68)	5.94 (4.80)
brain	1.54 (0.10)	1.30 (0.12)	0.66 (0.08)	0.25 (0.02)

^a Expressed as % injected dose per gram. Each value represents the mean (s.d.) for 5 animals at each interval. ^b Expressed as % injected dose per organ.

The biodistribution of the radioiodinated compounds ([¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2) was evaluated in normal mice (Table 2). A biodistribution study provides important information on brain uptake. The ideal NFT imaging agent should penetrate the blood–brain barrier well enough to deliver a sufficient dose into the brain while achieving rapid clearance from normal regions to result in a higher signal-to-noise ratio in the AD brain. The initial uptake of [¹²⁵I]TH2 at 2 min after the iv injection was relatively high (1.54%ID/g), whereas the retention at later time points was low (0.25%ID/g at 60 min post iv injection). These properties (a high initial uptake and fast washout from the normal mouse brain) suggest [¹²⁵I]TH2 to be a promising NFT imaging agent in the brain. On the other hand, [¹²⁵I]RH1 and [¹²⁵I]TH1 did not show marked initial uptake in the brain after iv injection (0.23 and 0.57%ID/g at 2 min postinjection, respectively), though the level of radioactivity in blood was similar to that for [¹²⁵I]TH2. To directly compare




Figure 3. Comparison of brain uptake of [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2 in normal mice.




Figure 4. In vitro autoradiograms of sections of AD brain labeled with [¹²⁵I]TH2 (A). The same sections were immunostained using an antibody against hyperphosphorylated tau (AT8) (B).

the uptake and washout rates of [¹²⁵I]RH1, [¹²⁵I]TH1, and [¹²⁵I]TH2, a combined plot is presented in Figure 3. The pharmacokinetics of [¹²⁵I]TH2 may provide a better pattern for the distribution of tau in AD brains. Although many factors such as molecular size, ionic charge, and lipophilicity affect the uptake of a compound into the brain, the lower lipophilicity of [¹²⁵I]TH2 may be one reason for the higher uptake of [¹²⁵I]TH2. We selected TH2 with high specific binding to tau aggregates and favorable pharmacokinetics in the mouse brain, for additional studies.

Next, the affinity of [¹²⁵I]TH2 for NFT was investigated using in vitro autoradiography in sections of human AD brain as shown in Figure 4. Autoradiographic images of [¹²⁵I]TH2 showed high levels of radioactivity in the brain tissue (Figure 4A). Furthermore, we confirmed that the hot spots of [¹²⁵I]TH2 corresponded with those of in vitro immunohistochemical staining in the same brain sections (Figure 4B).

To further investigate the binding to NFT in AD brain sections, we performed neuropathological fluorescent staining with TH2. Many NFTs were clearly stained with TH2 as reflected in the in vitro assay (Figure 5A). The labeling pattern was consistent with that observed on immunohistochemical labeling with an antibody specific for hyperphosphorylated tau (AT8) (Figure 5B), indicating that TH2 shows specific binding to NFTs. These results demonstrate the feasibility of the use of TH2 as a probe for detecting NFTs in the brains of AD patients.

In conclusion, we successfully designed and synthesized a new series of rhodanine and thiohydantoin derivatives as probes for the in vivo imaging of NFT in the brain. The derivatives, especially TH2, displayed higher affinity for tau aggregates than A β aggregates in experiments in vitro. Reflecting the results of the in vitro assays, TH2 clearly stained NFT in AD brain sections. In biodistribution experiments using normal mice, TH2 displayed good penetration of and fast washout from the brain, highly desirable characteristics for in vivo NFT imaging agents. Taken together, the present results suggest that [¹²⁵I]TH2 should be further investigated as a potential imaging agent for




Figure 5. Neuropathological staining of TH2 in 6 μ m sections from the hippocampus of an AD patient (A). The same sections were immunostained using an antibody against hyperphosphorylated tau (AT8) (B).

detecting tau pathology. Additional chemical modification of the rhodanine and thiohydantoin structure may lead to more useful NFT imaging agents for both PET and SPECT.

METHODS

General. All reagents were obtained commercially and used without further purification unless otherwise indicated. ^1H NMR spectra were obtained on a JEOL JNM400 with TMS as an internal standard. Coupling constants are reported in hertz. Multiplicity was defined by s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), and m (multiplet). Mass spectra were obtained on a SHIMADZU LCMS-2010 EV. HPLC was performed with a Shimadzu system (a LC-20AT pump with a SPD-10A UV detector, $\lambda = 254$ nm) using a Cosmosil C₁₈ column (Nakalai Tesque, SC₁₈-AR-II, 4.6×150 mm) and acetonitrile/water (7/3, 3/2, or 3/1) as the mobile phase at a flow rate of 1.0 mL/min. All key compounds were proven by this method to show >95% purity.

Chemistry. *5-(3-Iodophenyl)furan-2-carbaldehyde (1)*. To a solution of 5-formyl-2-furanboronic acid (280 mg, 2 mmol) and 1,3-diiodobenzene (660 mg, 2 mmol) in dimethoxyethane (15 mL) were added $(\text{Ph}_3\text{P})_4\text{Pd}$ (114 mg, 0.1 mmol) and 2 M Na_2CO_3 (4.6 mL). The reaction mixture was stirred for 3 h under reflux. Water (20 mL) was added to the cold mixture and extracted with ethyl acetate (20 mL \times 2). The organic phase was dried over Na_2SO_4 and filtered. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 155 mg of **1** (25.9%). ^1H NMR (400 MHz, CDCl_3) δ 6.85 (d, $J = 3.7$ Hz, 1H), 7.18 (t, $J = 8.0$ Hz, 1H), 7.31 (d, $J = 3.8$ Hz, 1H), 7.74–7.71 (m, 1H), 7.79–7.76 (m, 1H), 8.17 (t, $J = 1.7$ Hz, 1H), 9.67 (s, 1H).

Ethyl 2-(4-oxo-2-thioxothiazolidin-3-yl)acetate (2). A mixture of glycine ethyl ester hydrochloride (140 mg, 1 mmol) and bis(carboxymethyl)trithiocarbonate (224 mg, 1 mmol) in a mixed solvent of 2-propanol (6 mL) and triethylamine (0.6 mL) was stirred for 1 h under reflux. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 1/1) to give 177 mg of **2** (80.8%). ^1H NMR (400 MHz, CDCl_3) δ 1.29 (t, $J = 7.2$ Hz, 3H), 4.07 (s, 2H), 4.23 (q, $J = 7.2$ Hz, 2H), 4.72 (s, 2H).

Ethyl 2-(5-oxo-2-thioxoimidazolidin-1-yl)acetate (3). A mixture of glycine ethyl ester hydrochloride (140 mg, 1 mmol) and ethyl isothiocyanatoacetate (145 mg, 1 mmol) in a mixed solvent of acetonitrile (6 mL) and triethylamine (0.6 mL) was stirred for 10 min at room temperature. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 1/1) to give 170 mg of **3** (84.2%). ^1H NMR (400 MHz, CDCl_3) δ 1.30 (t, $J = 7.2$ Hz, 3H), 4.18 (s, 2H), 4.24 (q, $J = 7.2$ Hz, 2H), 4.57 (s, 2H).

(Z)-Ethyl 2-(5-((5-(3-iodophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetate (4, RH1). A mixture of **1** (30 mg, 0.1 mmol) and **2** (22 mg, 0.1 mmol) in dichloromethane (7 mL) and piperidine (20 μL) was stirred for 3 h at room temperature. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 38 mg of **4** (RH1) (76.2%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 1.21 (t, $J = 7.2$ Hz, 3H), 4.17 (q, $J = 7.2$ Hz, 2H), 4.84 (s, 2H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.43 (d, $J = 4.0$ Hz, 1H), 7.48 (d, $J = 4.0$ Hz, 1H), 7.80 (s, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.88 (d, $J = 8.0$ Hz, 1H), 8.25 (s, 1H). MS (APCI) m/z 500 [MH^+].

(Z)-Ethyl 2-(4-((5-(3-iodophenyl)furan-2-yl)methylene)-5-oxo-2-thioxoimidazolidin-1-yl)acetate (5, TH1). A mixture of **1** (30 mg, 0.1 mmol) and **3** (20 mg, 0.1 mmol) in dichloromethane (7 mL) and piperidine (20 μL) was stirred for 15 h at room temperature. The residue was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 21 mg of **5** (TH1) (43.6%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 1.21 (t, $J = 7.2$ Hz, 3H), 4.17 (q, $J = 7.2$ Hz, 2H), 4.61 (s, 2H), 6.68 (s, 1H), 7.28 (t, $J = 8.0$ Hz, 1H), 7.33 (d, $J = 4.0$ Hz, 1H),

7.38 (d, $J = 4.0$ Hz, 1H), 7.73 (d, $J = 8.0$ Hz, 1H), 7.99 (d, $J = 8.0$ Hz, 1H), 8.34 (s, 1H). MS (APCI) m/z 483 [MH^+].

3-(2-(1H-Imidazol-4-yl)ethyl)-2-thioxoimidazolidin-4-one (6). A mixture of histamine (111 mg, 1 mmol) and ethyl isothiocyanatoacetate (145 mg, 1 mmol) in acetonitrile (6 mL) was stirred for 10 min at room temperature. The solvent was removed, and the residue was purified by silica gel chromatography ($\text{CHCl}_3/\text{MeOH} = 4/1$) to give 167 mg of **6** (79.5%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 2.77 (t, $J = 8.0$ Hz, 2H), 3.86 (t, $J = 8.0$ Hz, 2H), 4.11 (s, 2H), 6.83 (s, 1H), 8.52 (s, 1H), 11.86 (br, s, 1H).

(Z)-3-(2-(1H-Imidazol-4-yl)ethyl)-5-((5-(3-iodophenyl)furan-2-yl)methylene)-2-thioxoimidazolidin-4-one (7). A mixture of **1** (30 mg, 0.1 mmol) and **6** (21 mg, 0.1 mmol) in dichloromethane (7 mL) and piperidine (20 μL) was stirred for 3 h at room temperature. The solvent was removed, and the residue was purified by silica gel chromatography (chloroform/MeOH = 9/1) to give 25 mg of **7** (TH2) (51.0%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 2.87 (t, $J = 7.6$ Hz, 2H), 4.02 (t, $J = 7.6$ Hz, 2H), 6.55 (s, 1H), 6.86 (s, 1H), 7.28 (t, $J = 8.0$ Hz, 1H), 7.31 (d, $J = 4.0$ Hz, 1H), 7.35 (d, $J = 4.0$ Hz, 1H), 7.58 (s, 1H), 7.72 (d, $J = 8.0$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 8.32 (s, 1H), 12.14 (br, s, 1H). MS (APCI) m/z 491 [MH^+].

5-(3-Bromophenyl)furan-2-carbaldehyde (8). To a solution of 5-formyl-2-furanboronic acid (676 mg, 4.8 mmol) and 3-bromiodobenzene (1.13 g, 4 mmol) in dimethoxyethane (30 mL) were added $(\text{Ph}_3\text{P})_4\text{Pd}$ (228 mg, 0.2 mmol) and 2 M Na_2CO_3 (9.6 mL). The reaction mixture was stirred for 2 h under reflux. Water (20 mL) was added to the cold mixture and extracted with ethyl acetate (20 mL \times 2). The combined organic layer was dried over Na_2SO_4 and filtered. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 306 mg of **8** (25.9%). ^1H NMR (400 MHz, CDCl_3) δ 6.86 (d, $J = 3.7$ Hz, 1H), 7.32 (d, $J = 3.8$ Hz, 1H), 7.34 (t, $J = 8.0$ Hz, 1H), 7.50–7.53 (m, 1H), 7.73–7.76 (m, 1H), 7.97 (t, $J = 1.7$ Hz, 1H), 9.68 (s, 1H).

5-(3-(Tributylstanny)phenyl)furan-2-carbaldehyde (9). A mixture of **8** (50 mg, 0.2 mmol), bis(tributyltin) (0.4 mL), and $(\text{Ph}_3\text{P})_4\text{Pd}$ (50 mg, 0.04 mmol) in a mixed solvent (9 mL, 5:4 dioxane/triethylamine mixture) was stirred for 3 h under reflux. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 9/1) to give 37 mg of **9** (40.0%). ^1H NMR (400 MHz, CDCl_3) δ 0.88–1.66 (m, 27H), 6.83 (d, $J = 3.8$ Hz, 1H), 7.32 (d, $J = 3.8$ Hz, 1H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.48–7.50 (m, 1H), 7.74–7.76 (m, 1H), 7.87 (t, $J = 1.2$ Hz, 1H), 9.66 (s, 1H).

(Z)-Ethyl 2-(4-oxo-2-thioxo-5-((5-(3-(tributylstanny)phenyl)furan-2-yl)methylene)thiazolidin-3-yl)acetate (10). A mixture of **9** (7 mg, 0.015 mmol) and **2** (3.5 mg, 0.016 mmol) in a mixed solvent of dichloromethane (3 mL) and piperidine (5 μL) was stirred for 15 h at room temperature. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 6 mg of **10** (56.6%). ^1H NMR (400 MHz, CDCl_3) δ 0.88–1.63 (m, 27H), 1.29 (t, $J = 7.0$ Hz, 3H), 4.24 (q, $J = 7.0$ Hz, 2H), 4.87 (s, 2H), 6.87 (d, $J = 3.7$ Hz, 1H), 6.99 (d, $J = 3.7$ Hz, 1H), 7.41–7.52 (m, 2H), 7.53 (s, 1H), 7.70–7.73 (m, 2H), 7.91 (s, 1H).

(Z)-Ethyl 2-(5-oxo-2-thioxo-4-((5-(3-(tributylstanny)phenyl)furan-2-yl)methylene)imidazolidin-1-yl)acetate (11). To a solution of **9** (10 mg, 0.022 mmol) and **3** (4.4 mg, 0.022 mmol) in dichloromethane (3 mL) was added piperidine (5 μL). The reaction mixture was stirred at room temperature overnight. The solvent was removed, and the residue was purified by silica gel chromatography (hexane/ethyl acetate = 7/3) to give 11 mg of **11** (74.0%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 0.84–1.54 (m, 27H), 1.21 (t, $J = 7.6$ Hz, 3H), 4.17 (q, $J = 7.2$ Hz, 2H), 4.60 (s, 2H), 6.67 (s, 1H), 7.22 (d, $J = 3.8$ Hz, 1H), 7.43–7.45 (m, 3H), 7.88–7.90 (m, 2H). MS (APCI) m/z 645 [$\text{M} - \text{H}^-$].

(Z)-3-(2-(1H-Imidazol-4-yl)ethyl)-2-thioxo-5-((5-(3-(tributylstanny)phenyl)furan-2-yl)methylene)imidazolidin-4-one (12). To a solution of **9** (65 mg, 0.14 mmol) and **6** (32 mg, 0.15 mmol) in dichloromethane

(7 mL) was added piperidine (20 μ L). The reaction mixture was stirred at room temperature overnight. The solvent was removed, and the residue was purified by silica gel chromatography ($\text{CHCl}_3/\text{MeOH} = 9/1$) to give 42 mg of **12** (45.9%). $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 0.84–1.64 (m, 27H), 2.87 (t, $J = 7.6$ Hz 2H), 4.01 (t, $J = 7.6$ Hz 2H), 6.55 (s, 1H), 6.84 (s, 1H), 7.20 (d, $J = 3.6$ Hz, 1H), 7.40–7.44 (m, 3H), 7.54 (s, 1H), 7.86–7.88 (m, 2H), 12.14 (br, s, 1H). MS (APCI) m/z 655 $[\text{MH}^+]$.

Iododestannylation Reaction. The radioiodinated forms of **4** (RH1), **5** (TH1), and **7** (TH2) were prepared from corresponding tributyltin derivatives by iododestannylation. Briefly, 50 μ L of H_2O_2 (3%) was added to a mixture of a tributyltin derivative (100 $\mu\text{g}/50$ μ L in EtOH), $^{125}\text{I}[\text{NaI}]$ (3.7–7.4 MBq, specific activity 81.4 TBq/mmol), and 100 μ L of 1 N HCl in a sealed glass vial. The reaction was allowed to proceed at room temperature for 5 min and terminated by the addition of 100 μ L of saturated aqueous NaHSO_3 . After addition of 100 μ L of a saturated aqueous NaHCO_3 , the reaction was extracted with ethyl acetate (1 mL). The extract was dried by passing through an anhydrous Na_2SO_4 column and then blown dry with a stream of nitrogen gas. The radioiodinated ligands were purified by HPLC on a Cosmosil C_{18} column with an isocratic solvent of $\text{H}_2\text{O}/\text{acetonitrile}$ (3/7, 2/3, or 1/3 for RH1, TH, or TH2, respectively) at a flow rate of 1.0 mL/min.

Binding Experiments Using Recombinant Tau and $A\beta$ (1–42) Aggregates. The 441 aa isoform of human tau was expressed from a cDNA clone in *Escherichia coli* and purified as described previously.³² Tau aggregates were prepared by incubating tau protein (1 mg/mL) in the presence of heparin (0.1 mg/mL) for 72 h with continuous shaking.³⁰ A solid form of $A\beta$ (1–42) was purchased from Peptide Institute (Osaka, Japan). Aggregation was carried out by gently dissolving the peptide (0.25 mg/mL) in a buffer solution (pH 7.4) containing 10 mM sodium phosphate and 1 mM EDTA. The solution was incubated at 37 $^\circ\text{C}$ for 42 h with gentle and constant shaking.

Thioflavin S was used as the tracer for the competition binding experiments. A mixture (100 μ L of 10% EtOH) containing RH1, TH1, and TH2 (final conc. 0–10 μM), thioflavin S (final conc. 1.5 μM), and tau aggregates (final conc. 0.2 μM) or $A\beta$ (1–42) aggregates (final conc. 2.2 μM) was incubated at room temperature for 30 min. Fluorescence intensity at an excitation wavelength of 510 nm for tau and 490 nm for $A\beta$ (1–42), respectively, was plotted, and values for the half-maximal inhibitory concentration (IC_{50}) were determined from displacement curves of three independent experiments using GraphPad Prism software (GraphPad Software, San Diego, CA). The inhibition constants (K_i) were calculated using the Cheng-Prusoff equation:³³ $K_i = \text{IC}_{50}/(1 + [L]/K_d)$, where $[L]$ is the concentration of thioflavin S used in the assay and K_d is the dissociation constant of thioflavin S. The K_d value for tau and $A\beta$ aggregates was 0.63 and 2.2 μM , respectively. (See Supporting Information.)

Binding Experiments Using Tau Monomers and Tau Aggregates. Tau aggregates were prepared as described above, and the tau monomer was used without aggregation. A mixture (300 μ L of 10% EtOH) containing $^{125}\text{I}[\text{RH1}]$, $^{125}\text{I}[\text{TH1}]$, and $^{125}\text{I}[\text{TH2}]$ (2.03 kBq) and the monomer or aggregates (final conc. 0.37 μM) were incubated at room temperature for 10 min. The reaction mixture was fractionated by size exclusion chromatography (PD-10 column, GE Healthcare) using phosphate-buffered saline (PBS) as the mobile phase, and the fraction in which tau aggregates or tau monomers were eluted was obtained. The radioactivity in this fraction was measured with a gamma counter (Perkin-Elmer, WIZARD 1470).

Biodistribution in Normal Mice. The experiments with animals were conducted in accordance with our institutional guidelines and approved by the Kyoto University Animal Care Committee. A saline solution (100 μ L) of ^{125}I -labeled derivatives (7.1–21.5 kBq) containing ethanol (10 μ L) was injected intravenously directly into the tail of ddY mice (5 weeks old, 22–25 g). The mice were sacrificed at various time

points postinjection. The organs of interest were removed and weighed, and radioactivity was measured with an automatic gamma counter (Perkin-Elmer, WIZARD³ 1480).

Neuropathological Staining of AD Brain Sections. Postmortem brain tissues from an autopsy-confirmed case of an AD (93-year-old female) patient were obtained and examined neuropathologically by conventional silver staining. Experiments were performed according to the regulations of the ethics committee of Kyoto University. Six-micrometer-thick serial sections of paraffin-embedded blocks of the hippocampus were used for staining. Paraffin sections were subjected to two 5 min incubations in xylene, and two 1 min incubations in 100% EtOH to completely deparaffinize them, followed by two 5 min washes in water and then PBS. Tissue sections were immersed in the compound solution (200 μM) containing 50% ethanol for 1 h. Finally, the sections were washed in 50% ethanol for 10 min. Fluorescent sections were viewed using a BZ-9000 fluoromicroscope equipped with a GFP-B filter. The sections were also immunostained with DAB as a chromogen using monoclonal antibodies against hyperphosphorylated tau (AT8)³⁰ as described previously.

In Vitro Autoradiography. Postmortem brain tissues from an autopsy-confirmed case of AD (72-year-old male) were obtained from BioChain Institute Inc. The presence and distribution of NFT in the sections were confirmed with immunohistochemical staining using a monoclonal tau antibody, AT8 (Wako), as reported. The sections were incubated with $^{125}\text{I}[\text{TH2}]$ (3.05 kBq/ml) for 1 h at room temperature. They were then dipped in saturated lithium carbonate in 50% EtOH (two 2 min washes) and washed with 50% EtOH (one 2 min wash), before being rinsed with water for 30 s. After drying, the ^{125}I -labeled sections were exposed to a Fuji Film imaging plate overnight.

■ ASSOCIATED CONTENT

S Supporting Information. Method for saturation assay with thioflavin S using recombinant tau and $A\beta$ _{1–42} aggregates; figure of binding of thioflavin S to tau aggregates and $A\beta$ aggregates. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*M.O.: phone, +81-75-753-4608; fax, +81-75-753-4568; e-mail, ono@pharm.kyoto-u.ac.jp. H.S.: phone, +81-75-753-4556; fax, +81-75-753-4568; e-mail, hsaji@pharm.kyoto-u.ac.jp.

Author Contributions

M.O. and H.S. oversaw and designed all experiments. S.H. performed synthetic chemistry work, and *in vitro* and *in vivo* experiments. K.M. performed biodistribution studies in normal mice. H.K. oversaw and performed synthetic chemistry work. Y.O., M.I. and R.T. oversaw and performed neuropathological staining of Alzheimer's brain sections. H.M. oversaw and designed binding experiments using tau protein.

Funding Sources

This study was supported by the Funding Program for Next Generation World-Leading Researchers and a Grant-in-aid for Young Scientists (A) and Exploratory Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

■ REFERENCES

(1) Selkoe, D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. *Physiol. Rev.* 81, 741–766.

- (2) Mathis, C. A., Wang, Y., and Klunk, W. E. (2004) Imaging β -amyloid plaques and neurofibrillary tangles in the aging human brain. *Curr. Pharm. Des.* 10, 1469–1492.
- (3) Nordberg, A. (2004) PET imaging of amyloid in Alzheimer's disease. *Lancet Neurol.* 3, 519–527.
- (4) Ono, M. (2009) Development of positron-emission tomography/single-photon emission computed tomography imaging probes for *in vivo* detection of β -amyloid plaques in Alzheimer's brains. *Chem. Pharm. Bull. (Tokyo)* 57, 1029–1039.
- (5) Agdeppa, E. D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G. M., Small, G. W., Huang, S. C., and Barrio, J. R. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β -amyloid plaques in Alzheimer's disease. *J. Neurosci.* 21, RC189.
- (6) Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S. C., and Barrio, J. R. (2002) Localization of neurofibrillary tangles and β -amyloid plaques in the brains of living patients with Alzheimer disease. *Am. J. Geriatr. Psychiatry* 10, 24–35.
- (7) Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., and Klunk, W. E. (2003) Synthesis and evaluation of ^{11}C -labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. *J. Med. Chem.* 46, 2740–2754.
- (8) Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergstrom, M., Savitcheva, I., Huang, G. F., Estrada, S., Aussen, B., Debnath, M. L., Barletta, J., Price, J. C., Sandell, J., Lopresti, B. J., Wall, A., Koivisto, P., Antoni, G., Mathis, C. A., and Langstrom, B. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann. Neurol.* 55, 306–319.
- (9) Ono, M., Wilson, A., Nobrega, J., Westaway, D., Verhoeff, P., Zhuang, Z. P., Kung, M. P., and Kung, H. F. (2003) ^{11}C -labeled stilbene derivatives as $\text{A}\beta$ -aggregate-specific PET imaging agents for Alzheimer's disease. *Nucl. Med. Biol.* 30, 565–571.
- (10) Verhoeff, N. P., Wilson, A. A., Takeshita, S., Trop, L., Hussey, D., Singh, K., Kung, H. F., Kung, M. P., and Houle, S. (2004) *In-vivo* imaging of Alzheimer disease β -amyloid with [^{11}C]SB-13 PET. *Am. J. Geriatr. Psychiatry* 12, 584–595.
- (11) Zhang, W., Oya, S., Kung, M. P., Hou, C., Maier, D. L., and Kung, H. F. (2005) F-18 polyethyleneglycol stilbenes as PET imaging agents targeting $\text{A}\beta$ aggregates in the brain. *Nucl. Med. Biol.* 32, 799–809.
- (12) Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., Dickinson-Rowe, K. L., Kung, H. P., Zhang, W., Kung, M. P., Skovronsky, D., Dyrks, T., Holl, G., Krause, S., Friebe, M., Lehman, L., Lindemann, S., Dinkelborg, L. M., Masters, C. L., and Villemagne, V. L. (2008) Imaging of amyloid β in Alzheimer's disease with ^{18}F -BAY94-9172, a novel PET tracer: proof of mechanism. *Lancet Neurol.* 7, 129–135.
- (13) Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., Itoh, M., Iwata, R., Yanai, K., and Arai, H. (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for *in vivo* detection of dense amyloid plaques in Alzheimer's disease patients. *J. Nucl. Med.* 48, 553–561.
- (14) Kung, M. P., Hou, C., Zhuang, Z. P., Zhang, B., Skovronsky, D., Trojanowski, J. Q., Lee, V. M., and Kung, H. F. (2002) IMPY: an improved thioflavin-T derivative for *in vivo* labeling of β -amyloid plaques. *Brain Res.* 956, 202–210.
- (15) Zhuang, Z. P., Kung, M. P., Wilson, A., Lee, C. W., Plossl, K., Hou, C., Holtzman, D. M., and Kung, H. F. (2003) Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting β -amyloid plaques in the brain. *J. Med. Chem.* 46, 237–243.
- (16) Kung, M. P., Hou, C., Zhuang, Z. P., Cross, A. J., Maier, D. L., and Kung, H. F. (2004) Characterization of IMPY as a potential imaging agent for β -amyloid plaques in double transgenic PSAPP mice. *Eur. J. Nucl. Med. Mol. Imaging* 31, 1136–1145.
- (17) Newberg, A. B., Wintering, N. A., Clark, C. M., Plossl, K., Skovronsky, D., Seibyl, J. P., Kung, M. P., and Kung, H. F. (2006) Use of ^{123}I IMPY SPECT to differentiate Alzheimer's disease from controls. *J. Nucl. Med.* 47, 78P.
- (18) Zhang, W., Kung, M. P., Oya, S., Hou, C., and Kung, H. F. (2007) ^{18}F -labeled styrylpyridines as PET agents for amyloid plaque imaging. *Nucl. Med. Biol.* 34, 89–97.
- (19) Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T. E., Kilbourn, M. R., Skovronsky, D., and Kung, H. F. (2009) Preclinical properties of ^{18}F -AV-45: a PET agent for $\text{A}\beta$ plaques in the brain. *J. Nucl. Med.* 50, 1887–1894.
- (20) Kung, H. F., Choi, S. R., Qu, W., Zhang, W., and Skovronsky, D. (2010) ^{18}F stilbenes and styrylpyridines for PET imaging of $\text{A}\beta$ plaques in Alzheimer's disease: a miniperspective. *J. Med. Chem.* 53, 933–941.
- (21) Johnson, A. E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J. A., Jureus, A., Strom, P., Norman, H., Farde, L., and Svensson, S. P. (2009) AZD2184: a radioligand for sensitive detection of β -amyloid deposits. *J. Neurochem.* 108, 1177–1186.
- (22) Jureus, A., Swahn, B. M., Sandell, J., Jeppsson, F., Johnson, A. E., Johnstrom, P., Neelissen, J. A., Sunnemark, D., Farde, L., and Svensson, S. P. (2010) Characterization of AZD4694, a novel fluorinated $\text{A}\beta$ plaque neuroimaging PET radioligand. *J. Neurochem.* 114, 784–794.
- (23) Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 42, 631–639.
- (24) Braak, H., and Braak, E. (1993) Entorhinal-hippocampal inter-connection in mnemonic disorders. *Hippocampus* 3 Spec. No. 239–246.
- (25) Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., and Hyman, B. T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann. Neurol.* 41, 17–24.
- (26) Gomez-Isla, T., Wasco, W., Pettingell, W. P., Gurubhagavatula, S., Schmidt, S. D., Jondro, P. D., McNamara, M., Rodes, L. A., DiBlasi, T., Growdon, W. B., Seubert, P., Schenk, D., Growdon, J. H., Hyman, B. T., and Tanzi, R. E. (1997) A novel presenilin-1 mutation: increased β -amyloid and neurofibrillary changes. *Ann. Neurol.* 41, 809–813.
- (27) Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., Thompson, P. M., Huang, S. C., Satyamurthy, N., Phelps, M. E., and Barrio, J. R. (2006) PET of brain amyloid and tau in mild cognitive impairment. *N. Engl. J. Med.* 355, 2652–2663.
- (28) Velasco, A., Fraser, G., Delobel, J., Ghetti, B., Lavenir, I., and Goedert, M. (2008) Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. *FEBS Lett.* 582, 901–906.
- (29) Mohorko, N., Repovs, G., Popovic, M., Kovacs, G. G., and Bresjanac, M. (2010) Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. *J. Neuropathol. Exp. Neurol.* 69, 405–414.
- (30) Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., Arai, H., Yanai, K., Sawada, T., and Kudo, Y. (2005) Quinoline and benzimidazole derivatives: candidate probes for *in vivo* imaging of tau pathology in Alzheimer's disease. *J. Neurosci.* 25, 10857–10862.
- (31) Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E. M., Mandelkow, E., and Waldmann, H. (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. *Angew. Chem., Int. Ed. Engl.* 46, 9215–9219.
- (32) Han, D., Qureshi, H. Y., Lu, Y., and Paudel, H. K. (2009) Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 *in vitro*. *J. Biol. Chem.* 284, 13422–13433.
- (33) Cheng, Y., and Prusoff, W. (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (I_{50}) of an enzymatic reaction. *Biochem. Pharmacol.* 22, 3099–3108.

Cite this: *Med. Chem. Commun.*, 2011, **2**, 596

www.rsc.org/medchemcomm

CONCISE ARTICLE

Phenyldiazenyl benzothiazole derivatives as probes for *in vivo* imaging of neurofibrillary tangles in Alzheimer's disease brains†Kenji Matsumura,^a Masahiro Ono,^{*,a} Shun Hayashi,^a Hiroyuki Kimura,^a Yoko Okamoto,^b Masafumi Ihara,^b Ryoosuke Takahashi,^b Hiroshi Mori^c and Hideo Saji^{*,a}

Received 4th February 2011, Accepted 17th March 2011

DOI: 10.1039/c1md00034a

This paper describes the synthesis and biological evaluation of novel phenyldiazenyl benzothiazole (PDB) derivatives as probes for imaging neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). We successfully synthesized three PDB derivatives using a diazo coupling reaction. In binding experiments *in vitro*, the compounds displayed higher affinity for tau aggregates than for A β aggregates. In fluorescent staining experiments using AD brain sections, **9** visualized NFTs clearly. No-carrier-added radioiodinated PDB derivatives were successfully prepared through an iododestannylation reaction from the corresponding tributyltin derivatives. [¹²⁵I]**9** labeled NFTs in sections of brain tissue from a patient with AD, but not a control. In biodistribution experiments using normal mice, the PDB derivatives displayed an uptake into the brain, sufficient for imaging NFTs, ranging from 0.94 to 3.2% ID g⁻¹, but a relatively slow washout. Although further modifications are necessary to improve the pharmacokinetics in the brain, PDB with high affinity for tau aggregates may be useful as a backbone structure to develop agents for imaging NFTs in AD brains.

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, irreversible memory loss, disorientation, and language impairment. Senile plaques (SPs) composed of β -amyloid (A β) peptides and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in the brain are two pathological hallmarks of AD.¹ Currently, there is no simple and definitive diagnostic method to detect SPs and NFTs in the brain without postmortem pathological staining of brain tissue. Therefore, techniques to image SPs and NFTs *in vivo* are strongly desired.

Recent success in developing several positron emission tomography (PET)/single photon emission computed tomography (SPECT) imaging agents targeting SPs has provided a window of opportunity to improve the diagnosis of AD. Compounds such as [¹¹C]-4-*N*-methylamino-4'-hydroxystilbene (SB-13),^{2,3} [¹¹C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PIB),^{4,6} [¹¹C]-2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole

(BF-227),⁷ [¹¹C]-2-[6-(methylamino)pyridin-3-yl]-1,3-benzothiazol-6-ol (AZD2184),⁸ [¹⁸F]-2-(1-(2-(*N*-(2-fluoroethyl)-*N*-methylamino)naphthalen-6-yl)ethylidene)malononitrile (FDDNP),^{9,10} (*E*)-4-(*N*-methylamino)-4'-(2-(2-(¹⁸F)-fluoroethoxy)ethoxy)ethoxy)stilbene (BAY94-9172),^{11,12} (*E*)-4-(2-(6-(2-(2-(¹⁸F)-fluoroethoxy)ethoxy)ethoxy)pyridin-3-ylvinyl)-*N*-methyl benzenamine (AV-45),¹³⁻¹⁵ and 2-(3-(¹⁸F)-fluoro-4-methylamino-phenyl)benzothiazol-6-ol (GE-067)¹⁶ have been tested clinically and demonstrated potential utility. Although numerous agents targeting SPs have been reported, there are few radiolabeled agents targeting NFTs.

Previous studies have confirmed that NFTs in the hippocampus and entorhinal cortex are positively correlated with the cognitive decline, whereas SPs are found in the brains of both AD patients and cognitively healthy individuals.¹⁷⁻²⁰ Therefore, NFTs could be a target for imaging by PET/SPECT, enabling a presymptomatic diagnosis and monitoring of the progression and effectiveness of new treatments currently being tested. A previous paper introduced three novel compounds, 4-[2-(2-benzoimidazolyl)ethenyl]-*N,N*-diethylbenzenamine (BF-126), 2-[(4-methylamino)phenyl]quinoline (BF-158), and 2-(4-amino-phenyl)quinoline (BF-170), for the *in vivo* imaging of NFTs in the AD brain.²¹ Although these probes displayed affinity for NFTs, they also bound to SPs. Since this report, there has been no publication regarding the development of agents to image NFTs despite their clinical significance. Therefore, PET/SPECT probes with greater affinity for NFTs are urgently required.

^aGraduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan. E-mail: ono@pharm.kyoto-u.ac.jp; Tel: +81-75-753-4556; Fax: +81-75-753-4568; hsaji@pharm.kyoto-u.ac.jp; +81-75-753-4568; +81-75-753-4608

^bGraduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan

^cDepartment of Neuroscience, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c1md00034a




Fig. 1 Chemical structure of ^{125}I -labeled PDB derivatives used in the present study.

Recently, a library containing 72,455 compounds was screened to determine the feasibility of distinguishing tau aggregates from $\text{A}\beta$ aggregates with small molecules. Among the compounds which bind to tau aggregates, a phenyldiazenyl benzothiazole (PDB) derivative, 4-[2-(5-methoxy-2-benzothiazolyl)diazenyl]-*N,N*-dimethyl-benzenamine (Fig. 1), showed the highest affinity for tau aggregates with two-fold selectivity to bind $\text{A}\beta$ aggregates.²² An even more recent paper reported that the PDB derivative strongly binds to tau aggregates at sites that at least partially overlap with those bound by ThS.²³ These findings prompted us to use the PDB as a core structure in the development of agents to image NFTs. We designed novel radioiodinated PDB derivatives, by substituting a methoxy group with a radioiodine at position 7 and introducing an electron-donating group (dimethylamino, monomethylamino, or amino group) at position 4 of the phenyl group (Fig. 1).

In the present study, we synthesized three radioiodinated PDB derivatives and evaluated their utility for imaging NFTs *in vivo*. To the best of our knowledge, this is the first time PDBs have been proposed as NFT imaging agents for detecting AD.


Results and discussion

The PDB derivatives were prepared as outlined in Scheme 1. We used a diazo coupling reaction to obtain compounds **1**, **2**, and **3**. The tributyltin derivatives (**4**, **5**, and **6**) were prepared from the corresponding compounds (**1**, **2**, and **3**) using a halogen-to-tributyltin exchange reaction catalyzed by Pd(0) in yields of 28.4, 23.7, and 67.3%, respectively. The tributyltin derivatives were used as the starting materials for radioiodination in the preparation of [^{125}I]**7**, [^{125}I]**8**, and [^{125}I]**9**. Novel radioiodinated PDB derivatives were obtained by an iododestannylation reaction using hydrogen peroxide as the oxidant which produced the desired radioiodinated ligands. It was anticipated that the no-carrier-added preparation would result in a final product bearing a theoretical specific activity similar to that of ^{125}I (81.4 TBq mmol^{-1}). The radiochemical identity of the radioiodinated

ligands was verified by co-injection with non-radioiodinated compounds from their HPLC profiles. [^{125}I]**7**, [^{125}I]**8**, and [^{125}I]**9** were each obtained in a radiochemical yield of 30–40% with a radiochemical purity of >99% after HPLC.

The affinity of PDB derivatives (**7**, **8**, and **9**) for tau aggregates was evaluated based on inhibition of the binding of thioflavin-S (ThS) to tau aggregates. As shown in Fig. 2A, all derivatives competed well with ThS to bind to tau aggregates, indicating that the binding sites of these compounds in tau aggregates partially overlapped with those of ThS. The K_i values for tau aggregates estimated for **7**, **8**, and **9** were 7.27, 1.37, and 0.48 nM, respectively (Table 1). Several clinical studies found that $\text{A}\beta$ imaging agents with K_i values of less than 10 nM successfully detected $\text{A}\beta$ plaques in the brain.^{24,25} Furthermore, the concentration of tau aggregates (~ 150 to 300 pmol mg^{-1} of wet tissue) was reported to be higher than that of $\text{A}\beta$ aggregates ($\sim 9 \text{ pmol mg}^{-1}$ of wet tissue) in the frontal and temporal cortices in late-stage AD.^{26,27} These findings indicate that **7**, **8**, and **9** have sufficiently high affinity for tau aggregates to image NFTs *in vivo*. Since these compounds inhibited the binding of ThS to tau aggregates, they may have affinity for the β -sheet structure common to both $\text{A}\beta$ and tau aggregates. To confirm the selectivity for tau aggregates relative to $\text{A}\beta$ aggregates, we evaluated the binding to $\text{A}\beta_{1-42}$ aggregates using a competitive assay with ThS. The three derivatives inhibited the binding of ThS to $\text{A}\beta_{1-42}$ aggregates and tau aggregates similarly (Fig. 2B). The K_i values for $\text{A}\beta_{1-42}$ aggregates estimated for **7**, **8**, and **9** were 6.40, 5.08, and 8.24 nM, respectively (Table 1). The ratio of the K_i values for tau and $\text{A}\beta_{1-42}$ aggregates was 0.88 for **7**, 3.71 for **8**, and 17.2 for **9**, indicating the electronegativity of the nitrogen atom of the aminophenyl group to play an important role in determining the selectivity. We also evaluated the affinity of SB-13,^{2,3} a well known $\text{A}\beta$ imaging probe, for tau and $\text{A}\beta_{1-42}$ aggregates according to the same procedure. The K_i values of SB-13 for tau and $\text{A}\beta_{1-42}$ aggregates were 82.2 and 81.2 nM, respectively, and the ratio of the K_i value for tau and $\text{A}\beta_{1-42}$ aggregates was 0.99. This result indicated that PDB derivatives, especially **9**, have higher selectivity for tau than SB-13. Then, we carried out further binding experiments with AD brain sections using **9**.

Next, [^{125}I]**9** was investigated for its affinity for NFTs by *in vitro* autoradiography in human AD brain sections (Fig. 3). Autoradiographic images of [^{125}I]**9** showed high levels of radioactivity in the brain tissue (Fig. 3A). Furthermore, we confirmed



Scheme 1 Synthetic route for PDB derivatives.



Table 1 Inhibition of the binding of thioflavin-S to tau and A β_{1-42} aggregates

Compound	K_i /nM ^a		K_i ratios of A β_{1-42} /tau
	Tau	A β_{1-42}	
7	7.27 \pm 0.09	6.40 \pm 0.57	0.88
8	1.37 \pm 0.02	5.08 \pm 0.45	3.71
9	0.48 \pm 0.01	8.24 \pm 0.08	17.2
SB-13	82.2 \pm 1.91	81.2 \pm 1.53	0.99

^a Values are the mean \pm standard error of the mean for three independent experiments.

that the hot spots of [¹²⁵I]9 corresponded with those of *in vitro* immunohistochemical staining against phosphorylated tau in sections of the same AD brain (Fig. 3B). Conversely, the normal human brain displayed no remarkable accumulation of [¹²⁵I]9 (Fig. 3D). In addition, little radioactivity accumulated in the white matter of the brain (Fig. 3A), indicating that nonspecific signals would be reduced *in vivo*. The hot spots in autoradiography also corresponded with those of *in vitro* immunohistochemical staining against A β_{1-42} (Fig. 3C), indicating that PDB derivatives do not have enough selectivity to show high contrast between NFTs and SPs in an autoradiographic study. This result was thought to reflect the higher affinity for both tau and A β_{1-42} aggregates of 9 ($K_i = 0.48$ and 8.24 nM, respectively) than SB-13 ($K_i = 82.2$ and 81.2 nM, respectively). Therefore, further structural modification of the PDB scaffold is needed to improve the selectivity for tau aggregates.

To further confirm the affinity of 9 for NFTs in the AD brain, fluorescent staining was carried out in sections of brain tissue (Fig. 4). Numerous fluorescent spots were detected in the entorhinal cortex of AD brain sections (Fig. 4A). The fluorescent labeling pattern corresponded to that obtained with ThS

**Fig. 2** Inhibition curves for the binding of thioflavin-S to tau (A) and A β_{1-42} (B) aggregates.**Fig. 3** Autoradiogram of [¹²⁵I]9 (A) and immunohistochemical staining with an antibody against phosphorylated tau (B) and A β_{1-42} (C) in brain sections from the same patient. Autoradiogram of [¹²⁵I]9 in a control brain section (D).

(Fig. 4B). These results, from *in vitro* autoradiography and fluorescent staining, demonstrate the feasibility of using [¹²⁵I]9 as a probe for detecting NFTs in the brains of AD patients.

One important requirement for an imaging agent of the brain is to penetrate the blood–brain barrier after an intravenous injection.²⁸ To evaluate the uptake of PDB derivatives in the brain, biodistribution experiments in normal mice were performed with radioiodinated forms ([¹²⁵I]7, [¹²⁵I]8, and [¹²⁵I]9) (Table 2). The initial uptake of [¹²⁵I]7, [¹²⁵I]8, and [¹²⁵I]9 2 min after the injection was 0.96, 1.03, and 0.94% ID g⁻¹, respectively. The radioactivity then showed a persistent increase, reaching 3.23, 3.13, and 2.89% ID g⁻¹. However, an imaging agent should also be rapidly washed out from the normal brain, in which there is no trapping mechanism for PDB derivatives.²⁵ Nevertheless, the retention of these probes in the normal mouse brain suggested extensive non-specific binding which would contribute to


**Fig. 4** Fluorescent staining with 9 (A) or thioflavin-S (B) in the entorhinal cortex of an AD brain section.

Table 2 Biodistribution of radioactivity after injection of PDB derivatives in normal mice^a

Tissue	Time after injection/min			
	2	10	30	60
	¹²⁵ I]7			
Blood	8.44 (1.10)	4.05 (0.41)	3.27 (0.15)	2.56 (0.26)
Liver	28.5 (2.51)	27.7 (0.51)	19.1 (1.69)	15.5 (1.32)
Kidney	9.54 (0.68)	10.4 (0.75)	9.70 (0.80)	8.88 (0.50)
Intestine	1.18 (0.41)	1.96 (0.60)	7.49 (1.35)	13.6 (3.53)
Spleen	5.78 (1.80)	8.54 (0.43)	8.07 (1.37)	7.84 (1.29)
Pancreas	3.36 (0.37)	5.25 (0.34)	5.22 (0.49)	4.04 (0.40)
Heart	12.8 (1.29)	7.28 (1.53)	5.32 (0.86)	3.58 (0.62)
Lung	18.8 (2.63)	10.0 (0.59)	6.56 (0.27)	5.23 (0.71)
Stomach ^b	0.76 (0.51)	1.28 (0.30)	2.28 (0.16)	3.69 (0.43)
Brain	0.96 (0.07)	1.56 (0.15)	2.50 (0.25)	3.23 (0.39)
	¹²⁵ I]8			
Blood	6.04 (0.75)	3.64 (0.36)	2.40 (0.31)	1.83 (0.14)
Liver	27.2 (2.66)	23.6 (2.24)	18.6 (2.71)	13.2 (1.36)
Kidney	17.4 (2.68)	17.4 (1.95)	10.8 (1.34)	7.67 (1.37)
Intestine	2.11 (0.41)	6.27 (0.56)	17.1 (0.86)	22.9 (5.47)
Spleen	13.8 (5.09)	17.8 (1.25)	12.2 (1.51)	9.74 (1.26)
Pancreas	4.90 (2.33)	10.7 (2.32)	9.80 (1.64)	7.20 (0.67)
Heart	21.2 (1.28)	12.3 (1.31)	7.2 (2.71)	5.24 (1.36)
Lung	45.7 (4.89)	17.9 (1.56)	8.96 (3.57)	8.96 (1.03)
Stomach ^b	0.81 (0.12)	1.47 (0.20)	2.03 (0.51)	2.28 (0.41)
Brain	1.03 (0.13)	2.02 (0.13)	2.90 (0.23)	3.13 (0.10)
	¹²⁵ I]9			
Blood	7.12 (1.11)	3.13 (2.20)	2.24 (1.88)	1.55 (1.88)
Liver	25.2 (3.23)	15.2 (4.31)	11.3 (4.85)	6.43 (1.43)
Kidney	11.1 (2.03)	11.3 (1.86)	8.04 (1.44)	9.53 (1.43)
Intestine	1.46 (0.33)	2.80 (0.72)	6.72 (0.76)	8.10 (0.90)
Spleen	5.70 (1.37)	5.92 (1.24)	4.93 (0.75)	3.15 (0.61)
Pancreas	3.04 (0.52)	4.96 (1.12)	5.15 (1.17)	8.11 (1.24)
Heart	12.6 (1.84)	7.15 (2.60)	4.25 (2.52)	4.13 (2.30)
Lung	29.3 (6.05)	11.7(7.63)	7.78 (7.64)	6.55 (8.09)
Stomach ^b	0.71 (0.09)	1.25 (0.11)	2.21 (0.70)	6.34 (6.61)
Brain	0.94 (0.18)	1.56 (0.35)	2.54 (0.40)	2.89 (0.42)

^a Each value represents the mean (SD) for 5 animals. ^b Expressed as % injected dose per organ.

a high level of background noise *in vivo*. The results suggest that PDB derivatives had unfavorable pharmacokinetics in normal mice, despite their good affinity for tau aggregates. Although factors such as molecular size, ionic charge, and lipophilicity affect a compound's uptake into and washout from the brain, previous studies suggest that lipophilicity is important to improving pharmacokinetics.^{2,29,30} Additional structural changes, that is, reducing lipophilicity by introducing a hydrophilic group, are necessary to improve the properties of the PDB derivatives. Improvements to the pharmacokinetics of radioactivity in the brain with high specific binding to tau aggregates should lead to the development of more useful PET/SPECT imaging agents based on the benzothiazole scaffold.

In conclusion, we successfully designed and synthesized three radioiodinated PDB derivatives as probes for the imaging of NFTs in the brain. In binding experiments *in vitro* using tau aggregates, the derivatives, especially **9**, displayed high affinity for tau aggregates. **9** clearly stained NFTs in experiments using autoradiography and fluorescent staining with AD brain sections, reflecting the results of the assays. In biodistribution experiments using normal mice, the PDB derivatives displayed good brain uptake, but persistent radioactivity in the brain made

them unsuitable for imaging NFTs *in vivo*. Appropriate structural changes to the PDB scaffold may lead to useful NFT imaging agents.

Acknowledgements

This study was supported by the Funding Program for Next Generation World-Leading Researchers, and a Grant-in-aid for Young Scientists (A) and Exploratory Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References

- 1 D. J. Selkoe, *Physiol. Rev.*, 2001, **81**, 741.
- 2 M. Ono, A. Wilson, J. Nobrega, D. Westaway, P. Verhoeff, Z. P. Zhuang, M. P. Kung and H. F. Kung, *Nucl. Med. Biol.*, 2003, **30**, 565.
- 3 N. P. Verhoeff, A. A. Wilson, S. Takeshita, L. Trop, D. Hussey, K. Singh, H. F. Kung, M. P. Kung and S. Houle, *Am. J. Geriatr. Psychiatr.*, 2004, **12**, 584.
- 4 C. A. Mathis, Y. Wang, D. P. Holt, G. F. Huang, M. L. Debnath and W. E. Klunk, *J. Med. Chem.*, 2003, **46**, 2740.
- 5 W. E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D. P. Holt, M. Bergstrom, I. Savitcheva, G. F. Huang, S. Estrada, B. Aussen, M. L. Debnath, J. Barletta, J. C. Price, J. Sandell, B. J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C. A. Mathis and B. Langstrom, *Ann. Neurol.*, 2004, **55**, 306.
- 6 A. Lockhart, J. R. Lamb, T. Osredkar, L. I. Sue, J. N. Joyce, L. Ye, V. Libri, D. Leppert and T. G. Beach, *Brain*, 2007, **130**, 2607.
- 7 Y. Kudo, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa, M. Maruyama, M. Itoh, R. Iwata, K. Yanai and H. Arai, *J. Nucl. Med.*, 2007, **48**, 553.
- 8 A. E. Johnson, F. Jeppsson, J. Sandell, D. Wensbo, J. A. Neelissen, A. Jureus, P. Strom, H. Norman, L. Farde and S. P. Svensson, *J. Neurochem.*, 2009, **108**, 1177.
- 9 E. D. Agdeppa, V. Kepe, J. Liu, S. Flores-Torres, N. Satyamurthy, A. Petric, G. M. Cole, G. W. Small, S. C. Huang and J. R. Barrio, *J. Neurosci.*, 2001, **21**, RC189.
- 10 K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa, V. Kepe, L. M. Ercoli, P. Siddarth, S. Read, N. Satyamurthy, A. Petric, S. C. Huang and J. R. Barrio, *Am. J. Geriatr. Psychiatr.*, 2002, **10**, 24.
- 11 W. Zhang, S. Oya, M. P. Kung, C. Hou, D. L. Maier and H. F. Kung, *Nucl. Med. Biol.*, 2005, **32**, 799.
- 12 C. C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K. L. Pike, G. O'Keefe, H. Tochon-Danguy, G. Chan, S. U. Berlangieri, G. Jones, K. L. Dickinson-Rowe, H. P. Kung, W. Zhang, M. P. Kung, D. Skovronsky, T. Dyrks, G. Holl, S. Krause, M. Friebe, L. Lehman, S. Lindemann, L. M. Dinkelborg, C. L. Masters and V. L. Villemagne, *Lancet Neurol.*, 2008, **7**, 129.
- 13 W. Zhang, M. P. Kung, S. Oya, C. Hou and H. F. Kung, *Nucl. Med. Biol.*, 2007, **34**, 89.
- 14 S. R. Choi, G. Golding, Z. Zhuang, W. Zhang, N. Lim, F. Hefti, T. E. Benedum, M. R. Kilbourn, D. Skovronsky and H. F. Kung, *J. Nucl. Med.*, 2009, **50**, 1887.
- 15 D. F. Wong, P. B. Rosenberg, Y. Zhou, A. Kumar, V. Raymond, H. T. Ravert, R. F. Dannals, A. Nandi, J. R. Brasic, W. Ye, J. Hilton, C. Lyketsos, H. F. Kung, A. D. Joshi, D. M. Skovronsky and M. J. Pontecorvo, *J. Nucl. Med.*, 2010, **51**, 913.
- 16 M. Koole, D. M. Lewis, C. Buckley, N. Nelissen, M. Vandenbulcke, D. J. Brooks, R. Vandenbergh and K. Van Laere, *J. Nucl. Med.*, 2009, **50**, 818.
- 17 P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte and B. T. Hyman, *Neurology*, 1992, **42**, 631.
- 18 H. Braak and E. Braak, *Hippocampus*, 1993, **3**, 239.
- 19 T. Gomez-Isla, R. Hollister, H. West, S. Mui, J. H. Growdon, R. C. Petersen, J. E. Parisi and B. T. Hyman, *Ann. Neurol.*, 1997, **41**, 17.
- 20 T. Gomez-Isla, W. Wasco, W. P. Pettingell, S. Gurubhagavata, S. D. Schmidt, P. D. Jondro, M. McNamara, L. A. Rodas, T. DiBlasi, W. B. Growdon, P. Seubert, D. Schenk, J. H. Growdon, B. T. Hyman and R. E. Tanzi, *Ann. Neurol.*, 1997, **41**, 809.

- 21 N. Okamura, T. Suemoto, S. Furumoto, M. Suzuki, H. Shimadzu, H. Akatsu, T. Yamamoto, H. Fujiwara, M. Nemoto, M. Maruyama, H. Arai, K. Yanai, T. Sawada and Y. Kudo, *J. Neurosci.*, 2005, **25**, 10857.
- 22 N. S. Honson, R. L. Johnson, W. Huang, J. Inglese, C. P. Austin and J. Kuret, *Neurobiol. Dis.*, 2007, **28**, 251.
- 23 N. S. Honson, J. R. Jensen, A. Abraha, G. F. Hall and J. Kuret, *Neurotoxic. Res.*, 2009, **15**, 274.
- 24 M. P. Kung, C. Hou, Z. P. Zhuang, A. J. Cross, D. L. Maier and H. F. Kung, *Eur. J. Nucl. Med. Mol. Imaging*, 2004, **31**, 1136.
- 25 H. F. Kung, S. R. Choi, W. Qu, W. Zhang and D. Skovronsky, *J. Med. Chem.*, 2010, **53**, 933.
- 26 S. Khatoon, I. Grundke-Iqbal and K. Iqbal, *J. Neurochem.*, 1992, **59**, 750.
- 27 J. Wang, D. W. Dickson, J. Q. Trojanowski and V. M. Lee, *Exp. Neurol.*, 1999, **158**, 328.
- 28 C. A. Mathis, Y. Wang and W. E. Klunk, *Curr. Pharm. Des.*, 2004, **10**, 1469.
- 29 M. Ono, H. Kawashima, A. Nonaka, T. Kawai, M. Haratake, H. Mori, M. P. Kung, H. F. Kung, H. Saji and M. Nakayama, *J. Med. Chem.*, 2006, **49**, 2725.
- 30 Y. Cheng, M. Ono, H. Kimura, S. Kagawa, R. Nishii and H. Saji, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 6141.



Effective synthesis of ^{99m}Tc tricarbonyl complexes by microwave heating

Naoya Harada^a, Hiroyuki Kimura^{a,*}, Masahiro Ono^a, Daisuke Mori^a, Yoshiro Ohmomo^b, Tetsuya Kajimoto^b, Hidekazu Kawashima^c, Hideo Saji^{a,*}

^a Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan

^b Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan

^c Kyoto University Hospital, 54 Shogoin Kawahara-cho, Kyoto 606-8507, Japan

ARTICLE INFO

Article history:

Received 16 April 2011

Received in revised form

19 August 2011

Accepted 23 August 2011

Keywords:

^{99m}Tc tricarbonyl complex

Microwave heating

SPECT

Radiopharmaceutical

ABSTRACT

Technetium-99m (^{99m}Tc) is one of the most frequently used nuclides for single-photon emission computed tomography (SPECT) imaging because of its radiochemical characteristics, such as gamma emission of suitable energy (141 keV) and adequate half-life (6.01 h). Although triaquatricarbonyl ^{99m}Tc cation ($[\text{}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$) has several advantages as a ^{99m}Tc -labeling agent, e.g., compact chelate size, chelate stability, and simplicity of preparation, its synthetic protocols should be improved. Because microwave heating is a convenient method for synthetic reactions, we studied the effect of microwave irradiation on the synthesis of ^{99m}Tc tricarbonyl complexes. We found several factors beneficial for the preparation of nuclear medicines. In particular, microwave heating promoted one-pot syntheses of ^{99m}Tc tricarbonyl chelates in a short time. In addition, the ^{99m}Tc tricarbonyl complex could be obtained using low concentrations of ligands.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Single-photon emission computed tomography (SPECT) is a potential tool for applications in nuclear medicine diagnosis, which can permit noninvasive diagnosis of diseases in early stages.

Technetium-99m (^{99m}Tc) is a frequently used nuclide for SPECT imaging because of its radiochemical characteristics such as gamma emission of suitable energy (141 keV) and adequate half-life (6.01 h). We can easily prepare ^{99m}Tc by using a ^{99}Mo – ^{99m}Tc generator, which yields $\text{Na } ^{99m}\text{TcO}_4$ as a ^{99m}Tc -containing molecule.

Among several species of ^{99m}Tc , $[\text{}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$, which can be prepared using a commercially available kit (IsoLink[®]) [1], has potential for use as a ^{99m}Tc -labeling agent because it forms compact [2] and stable [3] chelates with tridentate ligands, such as iminodiacetic acid (IDA), picolylamine monoacetic acid (PAMA), and *N,N*-dipicolylamine (DPA). However, for effective synthesis, the reaction of $[\text{}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ with ligands generally requires heating

[3–6]. Therefore, we studied improvements in the synthesis of ^{99m}Tc tricarbonyl chelates.

Microwave irradiation provides instantaneous reactions with effective heat conduction and dielectric heating. This method can be clinically used because it is easy and safe to attain reactions at high temperatures [7–9]. One-pot synthesis of ^{99m}Tc -labeled compounds has been previously reported in Ref. [4]. Such methodology is desirable for the synthesis of ^{99m}Tc -labeled compounds because the deprotection step can be avoided under acidic or basic conditions, which may be unsuitable for preparing peptidic probes and antibodies. For these reasons, we designed a novel synthetic protocol of ^{99m}Tc tricarbonyl chelates using microwave reactions. In this paper, we report the development of fast and effective syntheses of ^{99m}Tc tricarbonyl chelates by using microwave heating.

Nitrogen atoms coordinate preferentially to $[\text{Re}/^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ compared to oxygen atoms [2]. Although carboxyl groups are not present in DPA, they are contained in IDA and PAMA. Therefore, we hypothesized that IDA, PAMA, and DPA could react differently with $[\text{}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ under microwave irradiation. In addition, these ligands form ^{99m}Tc complexes with various electric charges: IDA forms anionic complexes, PAMA forms neutral complexes, and DPA forms cationic complexes. On the basis of this characteristic, we can synthesize several ^{99m}Tc -labeled probes with various electric charges. For these reasons, we evaluated the effects of microwave irradiation for the synthesis of ^{99m}Tc tricarbonyl complexes by using IDA, PAMA, and DPA.

Abbreviations: DPA, *N,N*-dipicolylamine; IDA, iminodiacetic acid; IDAME, dimethylester of iminodiacetic acid; PAMA, picolylamine monoacetic acid; PAMAE, ethylester of picolylamine monoacetic acid; RI, radioisotope; SPECT, single-photon emission computed tomography; UV, ultraviolet; HPLC, high-performance liquid chromatography; TLC, thin-layer chromatography.

* Corresponding authors. Tel.: +81 75 753 4566; fax: +81 75 753 4568.

E-mail addresses: hkimura@pharm.kyoto-u.ac.jp (H. Kimura), hsaji@pharm.kyoto-u.ac.jp (H. Saji).

2. Results and discussion

2.1. Analysis by radio-high performance liquid chromatography

Using an IsoLink kit, $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ was obtained in a good radiochemical yield (>95%) (data not shown).

Tc ($Z = 43$) appears in the middle of the second-row transition series in the periodic table of elements and has no stable isotopes. The development of Tc complexes as potential radiopharmaceuticals is facilitated by the use of Re, a group 7 congener of Tc in the periodic table. For this reason, Tc complexes are generally identified by comparison with high-performance liquid chromatography (HPLC) retention time of corresponding Re complexes.

We detected the complexes of Re with various ligands by UV spectra. The benzyl group of **2** was introduced as a chromophore for UV absorption. The HPLC retention times of the Re complexes were 10.9 (**3**), 18.9 (**4**), and 32.4 min (**5**) (Table 1). The HPLC retention times of the ^{99m}Tc complexes were 11.8 (**6**), 19.5 (**7**), and 33.3 min

Table 1
Structures of $^{99m}\text{Tc}/\text{Re}$ complexes.

No.	Abbreviation	Structure
3	Bn-IDA-Re	
4	PAMA-Re	
5	DPA-Re	
6	Bn-IDA- ^{99m}Tc	
7	PAMA- ^{99m}Tc	
8	DPA- ^{99m}Tc	

Table 2
HPLC retention time (min) of Re and ^{99m}Tc complexes.

Metal	Bn-IDA ^a -M ^d	PAMA ^b -M ^d	DPA ^c -M ^d
Re	10.9	18.9	32.4
^{99m}Tc	11.8	19.5	33.3

^a IDA = Iminodiacetic acid.

^b PAMA = Picolylamine monoacetic acid.

^c DPA = *N,N*-Dipicolylamine.

^d M = Metal.

(**8**) (Table 1). Because these RI peaks approximately corresponded to the UV peaks of Re complexes, they can be attributed to the peaks of the ^{99m}Tc complexes.

2.2. Determination of reaction temperature

In reactions of 300 μM of Bn-IDAME (dimethylester of iminodiacetic acid) with $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ at 75 °C, we could obtain **6** in significantly higher radiochemical yields by using microwave heating than by the conventional method, despite the same reaction temperature (Table 2; Entries 1 and 2). On the basis of these results, it suggested that microwave heating is superior for heat conduction than oil-bath heating.

In reactions at higher temperatures, radiochemical yields increased (Table 2; Entries 2, 3, and 4). This result suggests that $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ should be treated with ligands at 110 °C by microwave heating to effectively obtain ^{99m}Tc tricarbonyl complexes.

2.3. Microwave-promoted one-pot synthesis

The effects of microwave heating were observed more clearly in the reactions of $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ with Bn-IDAME or PAMAEE (ethylester of picolylamine monoacetic acid) compared to those with *N,N*-dipicolylamine (DPA). The yields of **6** increased more than 50-fold by using microwave heating (Table 3; Entries 1 and 2), and the yields of **7** increased by the same method (Table 3; Entries 3 and 4). Although the yields of **8** increased using microwave heating, the ratio (microwave/oil bath) was only 1.7 (Table 4; Entries 5 and 6). These results suggest that microwave heating promoted the hydrolysis step, which makes this method particularly effective for one-pot syntheses of ^{99m}Tc tricarbonyl complexes.

2.4. Microwave-accelerated synthesis of Bn-IDAME- ^{99m}Tc

By the conventional method, the radiochemical yield of the reaction of $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ with Bn-IDAME was only 6.4% at 1 min (Table 4). 15–30 min was required to produce **6** in good yields (Table 4). Meanwhile, the radiochemical yield of **6** reached a plateau in just 1 min by microwave heating. These results show that microwave heating enabled rapid production of ^{99m}Tc tricarbonyl complexes. Rapid synthesis is essential in nuclear medicine because it can suppress the decrease of radioactivity and

Table 3
Effect of temperature on the synthesis of Bn-IDA- ^{99m}Tc .

Entry	Ligand	[Ligand] (μM)	Method	Temp. (°C)	Time (min)	Yield (%)
1	Bn-IDAME	300	Oil bath	75	30	29.7
2	Bn-IDAME	300	Microwave ^a	75	30	51.5
3	Bn-IDAME	300	Microwave ^a	90	30	86.9
4	Bn-IDAME	300	Microwave ^a	110	30	98.5

^a Heated with microwave radiation (300 W, 17 bar maximum pressure).

Table 4
Ratios of radiochemical yields of ^{99m}Tc complexes by microwave heating to that by oil-bath heating.

Entry	Ligand	Product	[Ligand] (μM)	Method	Temp. (°C)	Time (min)	Yield (%)	Yield ratio (Microwave/oil bath)
1	Bn-IDAME	3	300	Microwave ^a	110	30	78.6	52.4
2	Bn-IDAME	3	300	Oil bath	75	30	1.5	
3	PAMAE	4	30	Microwave ^a	110	5	93.4	11.7
4	PAMAE	4	30	Oil bath	75	5	8.0	
5	DPA	5	30	Microwave ^a	110	5	84.9	1.7
6	DPA	5	30	Oil bath	75	5	49.0	

^a Heated by microwave radiation (300 W, maximum pressure was 17 bar).

avoiding long-time heating of precursors, particularly those of peptides and antibodies.

2.5. Decrease in concentrations of ligands by microwave heating

Although **6** could be obtained in more than 90% radiochemical yield by the conventional method, a high concentration of Bn-IDAME (30 mM) must be employed (Table 5). Moreover, the radiochemical yield of **6** was high (>90%) only when the concentration of Bn-IDAME was higher than 30 μM.

In contrast, by microwave heating, the radiochemical yield of **6** was high (>90%), although the concentration of Bn-IDAME was 30 μM. Moreover, we could obtain **6** by microwave heating with only 30 nM of Bn-IDAME (Table 6).

These results imply that concentrations of precursors can be decreased using microwave heating. Therefore, this method is considered to be beneficial for the preparation of probes. It is usually impossible to separate labeling precursors and ^{99m}Tc-labeled compounds. Free precursors may not only inhibit the binding of ^{99m}Tc-labeled compounds to target molecules but also cause adverse effects [11]. Such issues can be avoided by microwave heating.

3. Conclusion

We were able to more effectively synthesize ^{99m}Tc tricarbonyl complexes by microwave heating than by the conventional method. We rapidly obtained ^{99m}Tc tricarbonyl complexes by microwave heating using lower concentrations of ligands than that required by the conventional method. In addition, we demonstrated that microwave heating can be employed for ^{99m}Tc tricarbonyl complex synthesis. Hence, microwave heating can be efficiently used in nuclear medicine.

4. Material and methods

4.1. General procedure

Kieselgel 60 F-254 plates (Merck, Germany) were used for thin-layer chromatography (TLC). W-Prep 2XY (Yamazen, Japan) was used for silica gel column chromatography. Hi Flash™ silica gel

Table 5
Difference in reaction kinetics between microwave heating and oil bath for synthesis of **6**.

Method	Time (min)						Yield (%)
	1	5	10	15	30	60	
Microwave ^a	93.1	90.7	90.7	91.2	93.6	92.0	
Oil bath ^b	6.4	51.7	71.5	83.6	88.9	89.5	

^a Heated by microwave radiation (300 W, 17 bar maximum pressure) at 110 °C, [Bn-IDAME] was 30 mM.

^b Heated by oil bath at 75 °C, [Bn-IDAME] was 30 mM.

column 40 mm 60 Å (Yamazen) was used as the column. LC-20AD (Shimadzu, Japan) was used for HPLC. SPD-20A (Shimadzu) and NDW-351D (Aloka, Japan) were employed as ultraviolet (UV; λ = 254 nm) and radioisotope (RI) detectors, respectively. Cosmosil 5C18-AR-II 10 mm × 250 mm (Nacalai Tesque, Japan) was used as the HPLC column. Methanol (0.1% trifluoroacetic acid) and nanopure water (0.1% trifluoroacetic acid) were used as the mobile phase (flow rate = 2 mL/min). Nanopure water was prepared by MQ Integra15 (Nihon Millipore, Japan). ¹H and ¹³C NMR spectra were recorded on LNM-AL500 (JEOL, Japan) with CDCl₃, DMSO-*d*₆, or CD₃OD as a solvent and with tetramethylsilane as an internal standard (Euriso-Top, France). Mass spectra were recorded on LCMS-2010 EV (Shimadzu) or JMS-SX 102A QQ (JEOL). Discover (CEM Japan, Japan) was used as the microwave reactor. The maximum energy of microwave irradiation was set at 300 W, and the maximum pressure was set at 17 bar. All chemicals used were of reagent grade.

4.2. Selection of tridentate ligands

We selected three tridentate ligands that have amino groups, carboxyl groups, or pyridyl groups as the coordinating groups. To avoid hindrance in the synthesis of precursors, we protected free carboxyl groups as esters in this study.

4.3. Chemistry

4.3.1. Triaquatricarbonylrhenium bromide (**1**)

1 was prepared as previously reported in Ref. [10]. Briefly, 5 g of Re(CO)₅Br (Strem Chemicals, USA) was suspended in excess water and refluxed for 1 day. The reaction mixture was lyophilized to yield **1** as a chamois solid (4.4 g; 89% yield).

4.3.2. Dimethyl 2,2'-(benzylanedily)diacetate (Bn-IDAME) (**2**)


To a solution of dimethyl iminodiacetate (2.4 g; Fluka, USA) in 5 mL of anhydrous dimethylformamide, benzyl bromide (2.1 g; Aldrich, USA) and K₂CO₃ (2.1 g; Nacalai Tesque) were added. The mixture was stirred at 60 °C for 14 h and extracted with diethyl ether. The organic phase was washed with brine and dried with Na₂SO₄ (Nacalai Tesque). Purification by silica gel chromatography (hexane/AcOEt = 2/1) yielded **2** as a pale yellow oil (2.8 g; 87% yield). TLC R_f = 0.42 (hexane/AcOEt = 2/1). ¹H NMR (500 MHz,

Table 6
Effect of microwave heating on concentration of ligands for synthesis of **6**.

Method	[Ligand] (M)						Yield (%)
	3 × 10 ⁻²	3 × 10 ⁻³	3 × 10 ⁻⁴	3 × 10 ⁻⁵	3 × 10 ⁻⁶	3 × 10 ⁻⁷	
Microwave ^a	96.6	98.5	97.9	78.6	47.2	30.9	
Oil bath ^b	91.9	87.3	33.8	1.5	0.0	0.0	

^a Heated by microwave radiation (300W, 17 bar maximum pressure) at 110 °C for 30 min.

^b Heated by oil bath at 75 °C for 30 min.



Scheme 1. Synthesis of rhenium tricarbonyl complexes.

CD_3OD) $\delta = 7.35$ (d, $J = 7.4$ Hz, 2H), 7.30 (dd, $J = 7.4, 6.9$ Hz, 2H), 7.25 (d, $J = 6.9$ Hz, 1H), 3.87 (s, 2H), 3.70 (s, 6H), 3.51 (s, 4H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 51.4, 54.0, 58.0, 127.4, 128.4, 129.0, 138.2, 171.5$. FAB–HRMS; 252.1230 $[\text{M} + \text{H}]^+$ for $\text{C}_{13}\text{H}_{18}\text{NO}_4$ calcd 252.1236.

4.3.3. Bn-IDA–Re (3) $[\text{Re}(\text{CO})_3\{\text{NH}(\text{CH}_2\text{COO})_2\}]\text{H}$

To a solution of **2** (0.70 g) in 1,4-dioxane/water (6 mL/4 mL), NaOH (0.29 g) was added. The mixture was stirred at 60 °C for 0.4 h. To the mixture was added 6 N HCl to adjust the pH to 7. The solvent was removed under reduced pressure. The crude sample was added in a microwave vial and dissolved in 10 mL of water. To the vial was added **1** (0.40 g). The reaction vial was crimp sealed prior to microwave heating at 110 °C for 5 min. The reaction mixture was chilled, and then the precipitate was filtered and washed with ice-cold water to yield **3** (0.11 mg; 22%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) $\delta = 7.64$ (m, 2H), 7.40 (m, 3H), 4.33 (s, 2H), 3.88 (d, $J = 14.89$ Hz, 2H), 2.74 (d, $J = 14.89$ Hz, 2H). ESI-MS; 492 $[\text{M}]^-$ for $\text{C}_{14}\text{H}_{11}\text{NO}_7\text{Re}$.

4.3.4. PAMA–Re (4)

1 (0.20 g) and 0.10 g of PAMAEE (Tokyo Chemical Industry, Japan) were added to a microwave vial and dissolved in water/methanol (3 mL/0.5 mL). The reaction vial was crimp sealed prior to microwave heating at 110 °C for 5 min. The reaction mixture was chilled, and the precipitate was collected by filtration and washed with dichloromethane to yield **4** (white powder; 0.13 g; 56% yield). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) $\delta = 8.81$ (d, $J = 5.5$ Hz, 1H), 8.12 (dt, $J = 7.8, 1.1$ Hz, 1H), 7.75 (d, $J = 7.8$ Hz, 1H), 7.57 (t, $J = 6.6$ Hz, 1H), 7.22 (t, $J = 6.2$ Hz, 1H), 4.58 (d, $J = 16.7$ Hz, 1H), 4.50 (dd, $J = 5.1, 16.6$ Hz, 1H), 3.65 (dd, $J = 8.1, 17.3$ Hz, 1H), 3.25 (d, $J = 17.3$ Hz, 1H). ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) $\delta = 53.9, 62.0, 123.7, 125.4, 140.2, 152.0, 160.0, 179.5, 197.4, 197.5, 197.8$. FAB–HRMS; 437.0148 $[\text{M} + \text{H}]^+$ for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_5\text{Re}$ calcd 437.0131.

4.3.5. DPA–Re (5) $[\text{Re}(\text{CO})_3\{\text{NH}(\text{CH}_2\text{C}_5\text{H}_4\text{N})_2\}]\text{Br}$

1 (75 mg) and 0.37 g of DPA (Tokyo Chemical Industry) were added to a microwave vial and dissolved with 1 mL of methanol. The reaction vial was crimp sealed prior to microwave heating at 100 °C for 5 min. **5** was recrystallized from ethyl acetate/hexane (yellow solid; 69 mg; 77% yield). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) $\delta = 8.86$ (d, $J = 5.4$ Hz, 2H), 8.00 (dt, $J = 7.7, 1.4$ Hz, 2H), 7.62 (d,

$J = 7.7$ Hz, 2H), 7.42 (t, $J = 6.6$ Hz, 2H), 4.79 (dd, $J = 17.5, 6.0$ Hz, 2H), 4.74 (d, $J = 17.2$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 61.7, 123.3, 125.4, 140.2, 151.7, 161.0, 196.0, 196.1$. FAB–HRMS; found: 470.0515 $[\text{M}]^+$ for $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}_3\text{Re}$ calcd 470.0498.

4.3.6. Bn-IDA– $^{99\text{m}}\text{Tc}$ (6)

In the present study, we used $[\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ prepared as previously reported in Ref. [1]. Briefly, $\text{Na } ^{99\text{m}}\text{TcO}_4$ (Technescintio-10M[®], Nihon Medi-Physics, Japan) was added into an IsoLink[®] kit (Mallinckrodt, Netherlands), and the kit was heated at 100 °C for 20 min (247 MBq/mL). First, 240 μL of water and 80 μL of $[\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ were added to 240 μL of a methanol solution of **2** (70 mM, 7.0 mM, 70 μM , 7.0 μM , or 0.70 μM). Next, 6 M hydrochloric acid was added to the mixture to adjust the pH to 8. The mixture was heated on a microwave reactor or in an oil bath. HPLC t_R ; 11.8 min (methanol/water = 80/20).

4.3.7. PAMA– $^{99\text{m}}\text{Tc}$ (7)

First, 240 μL of water and 80 μL of $[\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ were added to 240 μL of methanol solution of PAMAEE (0.70 mM or 70 μM). Next, 6 M hydrochloric acid was added to the mixture to adjust the pH to 8. The mixture was heated in a microwave reactor or in an oil bath. HPLC t_R ; 19.5 min (methanol/water = from 40/60 to 60/40 over 30 min).

4.3.8. DPA– $^{99\text{m}}\text{Tc}$ (8)

First, 40 μL of water and 160 μL of $[\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ were added to 800 μL of a methanol solution of DPA (37.5 μM or 3.75 μM). Next, 6 M hydrochloric acid was added to the mixture to adjust the pH to 8. The mixture was heated on a microwave reactor or in an oil bath. HPLC t_R ; 33.3 min (methanol/water = from 30/70 to 40/60 over 20 min and then from 40/60 to 80/20 over 20 min) (Scheme 1).

4.4. Analysis by radio-HPLC

Radiochemical yields were calculated from the RI peak area of the HPLC chart. After reactions, the reaction samples were purified by HPLC. Then, radioactivity was dynamically plotted to obtain the RI chart. We calculated (radioactivity of objective compound)/(total radioactivity) as yield of $^{99\text{m}}\text{Tc}$ complexes.

4.5. Determination of reaction temperature

In the conventional method, reactions were conducted at 75 °C by heating in an oil bath [7]. Because this reaction temperature did not seem to be optimum, we investigated it further. First, 240 µL of water and 80 µL of $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ were added to 240 µL of a methanol solution of **2** (0.70 mM), and then the mixture was heated at 75 °C in an oil bath or in a microwave reactor. We also conducted reactions at 90 °C and 110 °C by using microwave heating. Radiochemical yields were calculated at fixed time points of 10, 15, and 30 min.

4.6. Evaluation of effects of microwave heating on ^{99m}Tc reactions

We investigated whether ^{99m}Tc complexes can be rapidly synthesized using microwave heating or the conventional method. Several concentrations of **2**, PAMAE, and DPA were reacted with $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ for 1–60 min.

4.7. Statistical test

StatView 5.0 (SAS, USA) was used for statistical analysis. A Bonferroni/Dunn test was used to assess the differences in the radiochemical yield between oil-bath heating and microwave heating. $p < 0.05$ was considered significant.

Acknowledgments

We thank FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan, for providing the IsoLink™ kit. This work was supported in part by a Grant-in-Aid for General Scientific Research from the Japan Society for the Promotion of Science.

References

- [1] G.E. Kodina, A.O. Malysheva, O.E. Klement'eva, A.A. Inkin, N.I. Gorshkov, A.A. Lumpov, D.N. Suglobov, J. Nucl. Radiochem. Sci. 6 (2005) 183–185.
- [2] R.S. Banerjee, K.M. Levadala, N. Lazarova, L. Wei, J.F. Valliant, A.K. Stephenson, J.W. Babich, K.P. Maresca, J. Zubieta, Inorg. Chem. 41 (2002) 6417–6425.
- [3] S. Alves, A. Paulo, J.D.G. Correia, L. Gano, C.J. Smith, T.J. Hoffman, I. Santos, Bioconjug. Chem. 16 (2005) 438–449.
- [4] D.R. van Staveren, P.D. Benny, R. Waibel, P. Kurz, J.-K. Pak, R. Alberto, Helv. Chim. Acta 88 (2005) 447–460.
- [5] M.B. Mallia, S. Subramanian, A. Mathur, H.D. Sarma, M. Venkatesh, S. Banerjee, J. Labelled Compd. Radiopharm. 51 (2008) 308–313.
- [6] C. Muller, C. Dumas, U. Hoffmann, P.A. Schubiger, R. Schibli, J. Organomet. Chem. 689 (2004) 4712–4721.
- [7] S.H. Park, H.J. Gwon, J.S. Park, K.B. Park, QSAR Comb. Sci. 23 (2004) 868–874.
- [8] V. Sridar, Curr. Sci. 74 (1998) 446–450.
- [9] M. Nuchter, B. Ondruschka, W. Bonrath, A. Gum, Green Chem. 6 (2004) 128–141.
- [10] N. Lazarova, S. James, J. Babich, J. Zubieta, Inorg. Chem. Commun. 7 (2004) 1023–1026.
- [11] S. Liu, D.S. Edwards, J.A. Barrett, Bioconjug. Chem. 8 (1997) 621–636.